<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2609245959
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MENVEO VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MENINGOCOCCAL GROUP A (NEISSERIA MENINGITIDIS) POLYSACCHARIDE VACCINE,MENINGOCOCCAL GROUP C (NEISSERIA MENINGITIDIS) POLYSACCHARIDE,MENINGOCOCCAL GROUP W (NEISSERIA MENINGITIDIS) POLYSACCHARIDE,MENINGOCOCCAL GROUP Y (NEISSERIA MENINGITIDIS) POLYSACCHARIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,5,5,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solution for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        207.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GSK Vaccines Srl" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GSK Vaccines Srl
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AH08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Menveo is a vaccine for use in children (from 2 months of age), adolescents and adults to prevent invasive disease caused by bacteria called Neisseria meningitidis groups A, C, W-135 and Y.</p><p>&nbsp;</p><p>These bacteria can cause serious and sometimes life-threatening infections such as meningitis and sepsis (blood poisoning).</p><p>&nbsp;</p><p>Menveo helps your body make its own protection (antibodies) against these</p><p>diseases.</p><p>The vaccine cannot cause the diseases that it protects you from.</p><p>&nbsp;</p><p>As with all vaccines, Menveo may not fully protect all people who are vaccinated.</p><p>&nbsp;</p><p>Menveo will only protect against diseases caused by the four groups of Neisseria meningitidis for which the vaccine has been developed. It will not protect against infections caused by any other groups of Neisseria meningitidis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Menveo</strong><!--[if supportFields]><b><span style='font-size:13.0pt;
font-family:"Arial",sans-serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_42ce6655-cdc3-4286-b586-a5ee44ef765d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to Menveo or any of the ingredients contained in Menveo (listed in section 6), including diphtheria toxoid. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.</p><p>&nbsp;</p><p>Check with your doctor if you think any of these apply to you.</p><p>&nbsp;</p><p><strong>Take special care with Menveo</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_64317d30-b470-484f-b74d-463be84b02fb
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Your doctor needs to know before you receive Menveo:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection with a high temperature. In these cases, the vaccination may be postponed until recovery. A minor infection such as a cold should not be a problem, but talk to your doctor first.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a weakened immune system. It is possible that the effectiveness of Menveo could be reduced in such individuals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you receive treatment that blocks the part of the immune system known as complement activation, such as eculizumab. Even if you have been vaccinated with Menveo you remain at increased risk of disease caused by the Neisseria meningitidis groups A, C, W-135 and Y bacteria.</p><p>&nbsp;</p><p>&nbsp;</p><p>Fainting can occur following, or even before, any needle injection; therefore, tell the doctor or nurse if you fainted with a previous injection.</p><p>&nbsp;</p><p><u>Only applicable to vial-syringe presentation</u></p><p>Latex-sensitive individuals:</p><p>The tip cap of the syringe may contain natural rubber latex. Please tell your doctor if you ever had an allergic reaction to latex.&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Menveo</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_d0b59f04-97bb-4473-8d72-8e01185bc717
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Menveo may be given at the same time as other vaccinations , but any other injected vaccines should preferably be given into a different limb from the site of the Menveo injection. Separate injection sites must be used if more than one vaccine is being administered at the same time. These include: diphtheria toxoid, acellular pertussis, tetanus toxoid (DTaP) vaccine, <em>Haemophilus influenza</em> type b vaccine (Hib); inactivated polio vaccine, measles, mumps, rubella (MMR) and varicella vaccines, pentavalent rotavirus vaccine, 7-valent pneumoccocal vaccine (PCV7), tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap), and human papilloma virus vaccine (HPV).</p><p>&nbsp;</p><p>Menveo must not be mixed with other vaccines or medicinal products in the same syringe.</p><p><strong>&egrave; Tell your doctor or pharmacist</strong> if you&rsquo;re taking any other medicines,<strong><em> </em></strong>if you&rsquo;ve taken any recently, or if you start taking a new one. This includes medicines bought without a prescription. or have recently received any other vaccine.&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b><span style='font-size:
13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_05de86a3-4706-4d16-96b2-422c9c20716b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>There is no information on whether Menveo affects the ability to drive or use machines. However, do not drive or use machines if you are feeling unwell.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Menveo is given</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;font-family:
"Arial",sans-serif'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1eb3797a-a52f-4258-9882-78317a5e440b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:13.0pt;font-family:
"Arial",sans-serif'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Menveo (0.5 ml) will be given to you by a doctor or nurse.</p><p>You will be informed if you should come back for a next dose of Menveo.</p><p>&nbsp;</p><p>Menveo will be injected into a muscle, usually in the thigh for infants or the upper arm for children, adolescents and adults.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><em>Children from 2 to 23 months of age</em></p><p><em>Infants starting vaccination from 2 to 6 months of age</em></p><p>Three injections followed by a fourth injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The interval between each of the three first injections should be at least 2 months.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fourth injection will be given in the second year of life (at 12-16 months).<br />&nbsp;</p><p>In some countries, an alternative schedule of only 3 doses may be used by your doctor or nurse.</p><p><em>Unvaccinated children from 7 to 23 months of age:</em></p><p>Two injections, with the second injection administered in the second year of life and at least 2 months after the first injection.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Children above 2 years of age, adolescents and adults:</em><br />&nbsp;</p><p>One injection.</p><p>&nbsp;</p><p>Please tell your doctor if you have received a previous injection with Menveo or another meningococcal vaccine.</p><p>&nbsp;</p><p>Your doctor will tell you if you need an additional injection of Menveo.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>If you miss a dose of Menveo</strong></p><p><strong><em>&nbsp;</em></strong></p><p>If you miss a scheduled injection, it is important that you make another appointment.</p><p>&nbsp;</p><p>Make sure your child finishes the complete vaccination course. If not, your child may not be fully protected.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Menveo can cause side effects, although not everybody gets them.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Children from 2 to 23 months of age:</em></p><p><em>&nbsp;</em></p><p><strong>Very common</strong> (these may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp; change in eating habits</p><p>&middot;&nbsp;&nbsp;&nbsp; persistent crying</p><p>&middot;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp; tenderness at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp; redness at the injection site (&le; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp; firmness at the injection site (&le; 50 mm)</p><p><strong>Common</strong> (these may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe tenderness at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&nbsp;</p><p><strong>Uncommon</strong> (these may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the injection site (&gt; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; firmness at the injection site (&gt; 50 mm)</p><p><strong><em>&nbsp;</em></strong></p><p><em>Children from 2 to 10 years of age:</em></p><p><em>&nbsp;</em></p><p><strong>Very common</strong> (these may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the injection site (&le; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; firmness at the injection site (&le; 50 mm)</p><p><strong>Common</strong> (these may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in eating habits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (&ge;38&ordm;C)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the injection site (&gt;50mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; firmness at the injection site (&gt;50mm)</p><p><strong>Uncommon</strong> (these may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching at the injection site</p><p>&nbsp;</p><p><em>Adolescents (from 11 years of age) and adults:</em></p><p><em>&nbsp;</em></p><p><strong>Very common</strong> (these may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the injection site (&le; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; firmness at the injection site (&le; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p><strong>Common</strong> (these may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness at the injection site (&gt; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; firmness at the injection site (&gt; 50 mm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (&ge; 38&deg;C)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&nbsp;</p><p><strong>Uncommon </strong>(these may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching at the injection site</p><p><strong><em>&nbsp;</em></strong></p><p><em>Post-marketing data</em></p><p><strong><em>&nbsp;</em></strong></p><p>Side effects that have been reported during marketed use include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged lymph nodes near injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions that may include severe swelling of the lips, mouth, throat (which may cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash and swelling of the hands, feet and ankles, loss of consciousness, very low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting; fits (convulsions) including fits associated with fever; numbness and weakness of the face; difficulties with balance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drooping of the upper eyelid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired hearing; ear pain; spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering of the skin called bullous conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site inflammation and swelling, including extensive swelling of the injected limb; tiredness&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormalities in blood tests for liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fall; head injury.</p><p>&nbsp;</p><p><strong>If you get side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_244350d8-b3db-4346-817d-86e5d83781e9
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Arial",sans-serif'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>&egrave;&nbsp; <strong>Tell your doctor or pharmacist </strong>if any of the side effects listed become<strong> severe or troublesome, </strong>or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the sight and reach of children.</li></ul><ul><li>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</li><li>Do not freeze.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light</p><ul><li>Do not use Menveo after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month.</li><li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Menveo contains</strong></p><p>After reconstitution, each dose (0.5 ml) contains 10 micrograms of meningococcal oligosaccharide of group A and 5 micrograms of meningococcal oligosaccharide of groups C, W-135 and Y; all 4 groups conjugated to <em>Corynebacterium diphtheriae</em> (CRM<sub>197</sub>) protein.&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p>The other ingredients are:</p><p><u>Powder</u></p><p>Potassium dihydrogen phosphate and sucrose.</p><p>&nbsp;</p><p><u>Solution</u></p><p>Sodium chloride, sodium dihydrogen phosphate monohydrate, disodium phosphate dihydrate and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Menveo looks like and contents of the pack
Menveo is presented as a powder and a solution to be mixed before injection.

The powder is white to off-white. 
The solution is colourless and clear.
Vial-Syringe presentation
•	Powder in vial with a stopper. 
•	Solution in pre-filled syringe with a tip cap. 
Menveo is available in a pack size of one dose: 1 vial of powder plus 1 pre-filled syringe. 
Vial-Vial presentation
•	Powder in vial with a stopper. 
•	Solution in vial with a stopper.

Menveo is available in a pack size of one dose: 1 vial of powder plus 1 vial of solution or in a pack size of 5 doses: 5 vials of powder plus 5 vials of solution.

Not all pack sizes may be marketed.

Instructions for use
The following information is intended for medical or healthcare professionals only.

Menveo must be prepared for administration by reconstituting the powder with the solution. The contents of the two components in the two different containers (MenA powder and MenCWY solution) are to be mixed prior to vaccination providing 1 dose of 0.5 ml.

For vial-vial presentation:
Menveo must be prepared for administration by reconstituting the powder (in vial) with the solution (in vial). The components of the vaccine should be visually inspected before and after reconstitution.

Using a syringe and suitable needle (21G, 40 mm length or 21 G, 1 ½ inch length), withdraw the entire contents of the vial of solution and inject into the vial of powder to reconstitute the MenA conjugate component.

Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.

Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

Prior to injection, change the needle with one suitable for the administration. Ensure that no air bubbles are present in the syringe before injecting the vaccine.

After reconstitution, the product should be used immediately. However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25°C.

For vial-syringe presentation:
Menveo must be prepared for administration by reconstituting the powder (in vial) with the solution (in pre-filled syringe). 
The components of the vaccine should be visually inspected before and after reconstitution.

Remove the tip cap from the syringe and attach a suitable needle for the withdrawal (21G, 1 ½ inch length or a 21G, 40 mm length). Use the whole contents of the syringe to reconstitute the powder.  

Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose. 

Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

Prior to injection, change the needle for one suitable for the administration.

After reconstitution, the product should be used immediately.  However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25°C.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Menveo is a trademark owned by or licensed to GSK group of companies.
©2023 GSK, all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>- GSK vaccines Srl Bellaria Rosia, Italy</p><p>Tel: (39) 0 577 243111</p><p>Fax: (39) 0 577 243074</p><p>Or alternatively by:</p><p>Italia S.p.A.Patheon -</p><p>Monza (MB) ,ITALY &ndash;iale G.B. Stucchi, 110 , 20900 V</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><ul><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline:19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-</strong><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicine out of reach of children.</p><p style="text-align:right">Council of Arab Health Ministers</p><p style="text-align:right">Union of Arab Pharmacists</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS version number: GDS 13
Version date: 1 Feb 2023

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إن لقاح مينفيو مخصص للاستخدام مع الأطفال (بداية من عمر شهرين) والمراهقين والبالغين للوقاية من الأمراض الغزوية التي تسببها مجموعات A وC وW-135 وY من بكتيريا النيسرية السحائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن أن تسبب هذه البكتيريا التهابات خطيرة ومهددة للحياة أحيانًا، مثل التهاب السحايا والإنتان<br />(تسمم الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">مينفيو يساعد جسمك على تكوين الحماية الخاصة به (الأجسام المضادة) من هذه الأمراض.</p><p dir="RTL">لا يمكن للقاح أن يسبب الأمراض التي يحميك منها.</p><p dir="RTL">وكما هو الحال في جميع اللقاحات، قد لا يحمي مينفيو بشكل كامل جميع الأشخاص الذين يتم تطعيمهم به.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يحمي مينفيو فقط من الأمراض التي تسببها المجموعات الأربع من النيسرية السحائية التي تم تطوير اللقاح من أجلها. ولن يحمي من الالتهابات التي تسببها أي مجموعات أخرى من النيسرية السحائية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل مينفيو في الحالات التالية</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_968318eb-ea66-476e-9ffc-c4aab29fed6b
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود حساسية (فرط الحساسية) لـ مينفيو، أو أي من المكونات التي يحتوي عليها مينفيو (المدرجة في القسم 6)، بما في ذلك ذوفان الخناق. قد تشمل علامات حدوث حساسية ظهور الطفح الجلدي المثير للحكة&rlm;‫ وضيق التنفس وتورم الوجه أو اللسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى الطبيب إذا كنت تعتقد أن أي من هذه الحالات تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي توخي الحذر عند استخدام مينفيو</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_3dc674b3-8105-4d90-ad70-a03f93c21f9c
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قبل تناول مينفيو، يحتاج طبيبك إلى معرفة ما يلي:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">إذا كنت تعاني من عدوى شديدة مع ارتفاع في درجة الحرارة. في تلك الحالات، قد يتم تأجيل التطعيم باللقاح حتى يتم الشفاء. ولا يجب اعتبار وجود عدوى بسيطة، مثل نزلة البرد، مشكلة، ولكن يجب استشارة الطبيب أولاً.</li><li dir="RTL">إذا كنت تعاني من ضعف الجهاز المناعي. فمن الممكن أن تقل فعالية مينفيو عند هؤلاء الأشخاص.</li><li dir="RTL">إذا تلقيت العلاج الذي يحظر جزء من الجهاز المناعي المعروف باسم التفعيل التكميلي ، مثل eculizumab. حتى لو تم تطعيمك بلقاح المنفيو ، فإنك تظل عرضة لخطر الإصابة بالأمراض الناجمة عن مجموعات البكتيريا النيسرية السحائية A و C و W-135 و Y.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث الإغماء بعد، أو حتى قبل، أي حقن بالإبرة، لذلك، أخبر الطبيب أو الممرضة إذا كنت قد تعرضت للإغماء بسبب الحقن في السابق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تنطبق فقط على أشكال القنينة والمحقنة</u></p><p dir="RTL">الأشخاص الذين لديهم حساسية من اللاتكس:</p><p dir="RTL">قد يحتوي غطاء رأس المحقنة على لاتكس من المطاط الطبيعي. يرجى إخبار الطبيب إذا كنت قد حدث لك في أي وقت مضى تفاعل حساسية من اللاتكس.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>باستخدام أدوية أو لقاحات أخرى</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_1709f9b1-75bd-4149-9b3e-e386033cb8a1
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا ، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية ، أو تلقيت مؤخرًا أي لقاح آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء Menveo في نفس الوقت مثل اللقاحات الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم استخدام موقع حقن مختلف لكل نوع من اللقاحات.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_da9c8d1a-6893-4523-b320-b428f1bf08a4
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">ينبغي استشارة الطبيب أو الصيدلاني قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تتوفر معلومات عما إذا كان مينفيو يؤثر على القدرة على القيادة أو استخدام الآلات. إلا أنه يجب تجنب القيادة أو استخدام الآلات إذا كنت تشعر أنك لست على ما يرام.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية إعطاء مينفيو</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_a6f65ac1-006b-46ca-903e-c89c82abe8a9
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يتم إعطاؤك مينفيو (0,5 مل) بواسطة الطبيب أو الممرضة.</p><p dir="RTL">سيتم إبلاغك ما إذا كان يجب عليك العودة مرة أخرى لتلقي جرعة لاحقة من مينفيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم حقن مينفيو في العضلات، عادةً في الفخذ بالنسبة للرضع أو أعلى الذراع بالنسبة للأطفال والمراهقين والبالغين.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><em>الأطفال من عمر شهرين إلى </em><em>23</em><em> شهرًا</em></p><p dir="RTL"><em>الرضع الذين يتم بدء تطعيمهم باللقاح من عمر شهرين إلى </em><em>6</em><em> أشهر</em></p><p dir="RTL">ثلاث حُقَن متبوعة بحقنة رابعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يكون الفاصل الزمني بين كل من الحُقَن الثلاثة الأولى شهرين على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إعطاء حقنة رابعة في السنة الثانية من العمر (12 إلى 16 شهرًا).<br />&nbsp;</p><p dir="RTL">في بعض البلدان، قد يستخدم الطبيب أو الممرضة جدولًا بديلاً يتضمن ثلاث جرعات فقط.</p><p dir="RTL"><em>الأطفال الذين لم يتم تطعيمهم من عمر </em><em>7</em><em> أشهر إلى </em><em>23</em><em> شهرًا:</em></p><p dir="RTL">حقنتين، ويتم إعطاء الحقنة الثانية في السنة الثانية من العمر وبعد شهرين على الأقل من الحقنة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال الذين تزيد أعمارهم عن عامين والمراهقين والبالغين:</em><br />&nbsp;</p><p dir="RTL">حقنة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إخبار طبيبك إذا كنت قد تلقيت حقنة سابقة من مينفيو أو لقاح آخر للمكورات السحائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك إذا كنت بحاجة إلى حقنة إضافية من مينفيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، فيمكنك سؤال الطبيب أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تفويت جرعة مينفيو</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا فاتتك حقنة مجدولة، فمن المهم أن تقوم بتحديد موعد آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكد من استكمال طفلك لبرنامج التطعيم بالكامل. فإذا لم يحدث ذلك، قد لا يكون طفلك محميًا حماية كاملة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن أن يتسبب مينفيو في آثار جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال من عمر شهرين إلى </em><em>23</em><em> شهرًا:</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في العادات الغذائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بكاء مستمر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة الانفعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عند الضغط على موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&le; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&le; 50 مم)</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب حتى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد عند الضغط على موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى شخص واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&gt; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&gt; 50 مم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال من عمر شهرين إلى </em><em>10</em><em> سنوات:</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة الانفعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بعدم الراحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&le; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&le; 50 مم)</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب حتى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في العادات الغذائية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (&ge; 38 درجة مئوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&gt; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&gt; 50 مم)</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى شخص واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في موضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>المراهقون (من عمر </em><em>11</em><em> سنة) والبالغين:</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&le; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&le; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بعدم الراحة</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب حتى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في موضع الحقن (&gt; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس في موضع الحقن (&gt; 50 مم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (&ge; 38 درجة مئوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى شخص واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في موضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>بيانات بعد التداول</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية التي تم الإبلاغ عنها أثناء التداول ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد اللمفاوية بالقرب من موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية قد تشمل التورم الحاد في الشفتين والفم والحلق (والذي قد يسبب صعوبة في البلع) وصعوبة التنفس مع أزيز صدري أو السعال والطفح الجلدي وتورم اليدين والقدمين والكاحلين وفقدان الوعي وانخفاض ضغط الدم الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، النوبات (التشنجات)، بما في ذلك النوبات المرتبطة بالحمى، الخدر وضعف الوجه، صعوبات في التوازن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدلى الجفن العلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف السمع؛ ألم في الأذن؛ الإحساس بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الجلد تسمى حالات التقرحات الفقاعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وتورم في موضع الحقن، بما في ذلك تورم على نطاق واسع في الطرف المحقون؛ تعب&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج فحوصات الدم غير الطبيعية لوظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط؛ إصابة بالرأس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإصابة بالآثار الجانبية</strong><!--[if supportFields]><b><span lang=AR-SA
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-size:13.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'>VAULT_ND_cfff042c-95fa-47a4-90bb-88ce7c8a370c
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-size:13.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil;&nbsp;&nbsp; <strong>أبلغ الطبيب أو الصيدلاني</strong> في حالة تفاقم أي من الأعراض الجانبية الموضحة هنا أو إذا أصبحت<strong> مزعجة</strong>، أو إذا لاحظت أية أعراض جانبية غير مبيَّنة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">يُحفظ بعيدًا عن متناول الأطفال.</li></ul><ul><li dir="RTL">يُحفظ في الثلاجة (بين 2 و8 درجات مئوية).</li><li dir="RTL">يجب عدم تجميده.</li><li dir="RTL">يُحفظ في العبوة الأصلية للحماية من الضوء</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم مينفيو بعد تاريخ انتهاء الصلاحية المدوَّن على العبوة الكرتونية بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية برميها في مياه الصرف أو ضمن المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات مينفيو</strong></p><p dir="RTL">بعد المزج، تحتوي كل جرعة (0,5 مل) على 10 ميكروجرام من اللقاح قليل السكاريد للوقاية من المكورات السحائية للمجموعة A و5 ميكروجرام من اللقاح قليل السكاريد للوقاية من المكورات السحائية للمجموعات C<br />وW-135 وY، جميع الأربع مجموعات المترافقة مع بروتين <em>Corynebacterium diphtheriae</em> (CRM<sub>197</sub>).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><u>المسحوق</u></p><p dir="RTL">فوسفات ثنائي هيدروجين البوتاسيوم والسكروز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المحلول</u></p><p dir="RTL">كلوريد الصوديوم، وأحادي هيدرات فوسفات ثنائي هيدروجين الصوديوم وثنائي هيدرات فوسفات ثنائي الصوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل مينفيو ومحتويات العبوة</strong></p><p dir="RTL">يتوفر مينفيو كمسحوق ومحلول للمزج قبل الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لون المسحوق أبيض إلى أبيض مائل للاصفرار.</p><p dir="RTL">المحلول عديم اللون ورائق.</p><p dir="RTL"><u>شكل القنينة والمحقنة</u></p><ul><li dir="RTL">مسحوق في قنينة بسدادة.</li><li dir="RTL">المحلول في محقنة مملوءة مسبقًا بغطاء.</li></ul><p dir="RTL">مينفيو متوفر في عبوة بحجم جرعة واحدة: قنينة واحدة من المسحوق بالإضافة إلى محقنة واحدة مملوءة مسبقًا.</p><p dir="RTL"><u>شكل القنينة والقنينة</u></p><ul><li dir="RTL">مسحوق في قنينة بسدادة.</li><li dir="RTL">محلول في قنينة بسدادة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">مينفيو متوفر في عبوة بحجم جرعة واحدة: قنينة واحدة من المسحوق بالإضافة إلى قارورة واحدة من المحلول أو في عبوة بحجم 5 جرعات: 5 قنينات من المسحوق بالإضافة إلى 5 قنينات من المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL"><strong>المعلومات التالية خاصة باختصاصيي الرعاية الصحية فقط.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تحضير مينفيو للتناول عن طريق مزج المسحوق بالمحلول. يجب أن مزج محتويات المكونين في الحاويتين المختلفتين (مسحوق MenA ومحلول MenCWY) قبل إعطاء اللقاح، والذي يعطي جرعة واحدة مكونة من 0,5 مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بالنسبة لشكل القنينة والقنينة</u></p><p dir="RTL">يجب تحضير مينفيو للتناول عن طريق مزج المسحوق (في القنينة) بالمحلول (في القنينة). يجب فحص مكونات اللقاح بالعين قبل وبعد المزج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">باستخدام محقنة وإبرة مناسبة (مقاس 21 بطول 40 مم أو مقاس 21 بطول 1,5 بوصة)، قم بسحب محتويات قنينة المحلول بالكامل وحقنها في قنينة المسحوق لمزج مكون MenA المقترن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقلب القنينة ورجها بقوة ثم اسحب 0,5 مل من المنتج الممزوج. يرجى ملاحظة أنه من الطبيعي أن تبقى كمية قليلة من السائل في القنينة بعد سحب الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج، يكون اللقاح عبارة عن محلول شفاف عديم اللون أو يميل إلى اللون الأصفر الفاتح وخالٍ من الجزيئات الغريبة المرئية. في حالة وجود أي جسيمات غريبة و/أو ملاحظة تغير في الجانب المادي، لا تقم بإعطاء اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الحقن، قم بتغيير الإبرة بإبرة مناسبة لإعطاء اللقاح. تأكد من عدم وجود فقاعات هواء في المحقنة قبل حقن اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج، يجب استخدام المنتج على الفور. إلا أنه، تبين الاستقرار الكيميائي والمادي بعد المزج لمدة 8 ساعات في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>بالنسبة لشكل القنينة والمحقنة</u></p><p dir="RTL">يجب تحضير مينفيو للتناول عن طريق مزج المسحوق (في القنينة) بالمحلول (في المحقنة المملوءة مسبقًا).</p><p dir="RTL">يجب فحص مكونات اللقاح بالعين قبل وبعد المزج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بإزالة الغطاء من المحقنة وتثبيت إبرة مناسبة للسحب (مقاس 21 بطول 1,5 بوصة أو مقاس 21 بطول 40 مم). استخدم محتويات المحقنة بالكامل لمزج المسحوق.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقلب القنينة ورجها بقوة ثم اسحب 0,5 مل من المنتج الممزوج. يرجى ملاحظة أنه من الطبيعي أن تبقى كمية قليلة من السائل في القنينة بعد سحب الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج، يكون اللقاح عبارة عن محلول شفاف عديم اللون أو يميل إلى اللون الأصفر الفاتح وخالٍ من الجزيئات الغريبة المرئية. في حالة وجود أي جسيمات غريبة و/أو ملاحظة تغير في الجانب المادي، لا تقم بإعطاء اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الحقن، قم بتغيير الإبرة بإبرة مناسبة لإعطاء اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج، يجب استخدام المنتج على الفور. إلا أنه، تبين الاستقرار الكيميائي والمادي بعد المزج لمدة 8 ساعات في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التخلص من أي منتج طبي غير مستخدم أو نفايات وفقًا للتنظيمات المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مينفيو هو علامة تجارية مملوكة&nbsp; أو مرخصة لها لمجموعة شركات جلاكسو سميث كلاين..</p><p dir="RTL">&copy; 2023 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p>- GSK vaccines Srl Bellaria Rosia, Italy</p><p>Tel: (39) 0 577 243111</p><p>Fax: (39) 0 577 243074</p><p>Or alternatively by:</p><p>Patheon Italia S.p.A. -</p><p>Monza (MB) ,ITALY &ndash;iale G.B. Stucchi, 110 , 20900 V</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك التسويق المعتمد:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL">* شركة تنتمي إلى مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL"><strong>للاستفسار عن أية معلومات عن هذا المستحضر الدوائي، يرجى الاتصال بالأرقام التالية</strong><strong>:</strong></p><p dir="RTL"><strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 -12)-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحمول : 9882-904-56- 966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><ul><li dir="RTL">الاتصال بالرقم الموحد: 19999</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul><p dir="RTL"><strong>- </strong><strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><ul><li dir="RTL">هاتف: 6536666-12-966+</li><li dir="RTL">جوال: 9882-904-56-966+</li><li dir="RTL">البريد الإلكتروني: <u>s</u>audi.safety@gsk.com</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/<u> </u></p><ul><li dir="RTL">ص. ب. رقم 55850، جدة 21544، المملكة العربية السعودية</li></ul></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL"><strong>حول هذا الدواء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء هو منتج يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرف الدواء لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.</p><p>مجلس وزراء الصحة العرب</p><p>اتحاد الصيادلة العرب</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: GDS 13
تاريخ الإصدار: 1 فبراير2023

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meningococcal Group A, C, W-135 and Y conjugate vaccine
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, 1 dose (0.5 ml) contains:				
Meningococcal group A oligosaccharide	 			           10 micrograms
Conjugated to Corynebacterium diphtheriae (CRM197) protein    16.7 to 33.3 micrograms
Meningococcal group C oligosaccharide	 		                         5 micrograms
Conjugated to CRM197 protein                                                         7.1 to 12.5 micrograms
Meningococcal group W-135 oligosaccharide		                         5 micrograms
Conjugated to CRM197 protein                                                           3.3 to 8.3 micrograms
Meningococcal group Y oligosaccharide		                    	             5 micrograms
Conjugated to CRM197 protein                                                         5.6 to 10.0 micrograms 

The meningococcal group A conjugated component is presented as white to off-white powder. 
The meningococcal group C, W-135 and Y conjugated components are presented as a colourless clear solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solution for solution for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Menveo is indicated for active immunisation of children (from 2 months of age), adolescents and adults to prevent invasive meningococcal disease caused by <em>Neisseria meningitidis</em> groups A, C, W-135 and Y.</p><p>&nbsp;</p><p>The use of this vaccine should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><!--[if supportFields]><b><span style='font-size:10.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"MS Mincho";
text-transform:uppercase;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_9d37e4b1-b475-4c51-a5d9-0d85726115fc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><em>Primary vaccination (see Pharmacodynamic effects):</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Children from 2 to 23 months of age</p></td><td rowspan="2" style="vertical-align:top"><p>Children from 2 to 10 years of age</p></td><td rowspan="2" style="vertical-align:top"><p>Adolescents (from 11 years of age) and adults</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infants initiating vaccination from 2 to 6 months of age</p></td><td style="vertical-align:top"><p>Unvaccinated infants and children from 7 to 23 months of age</p></td></tr><tr><td><p>4-dose schedule</p></td><td><p>3-dose schedule*</p></td><td><p>2-dose schedule</p></td><td><p>1 single dose</p></td><td><p>1 single dose</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; 3 doses, with a minimum interval of 2 months between each dose</p><p>-&nbsp;&nbsp; 4<sup>th</sup> dose during the second year of life (at 12-16 months)</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp; 1<sup>st</sup> dose from 2 months of age</p><p>-&nbsp;&nbsp; 2<sup>nd</sup> dose 2 months after 1<sup>st</sup> dose</p><p>-&nbsp;&nbsp; 3<sup>rd</sup> dose as early as possible during the second year of life</p></td><td style="vertical-align:top"><p>2 doses, with a minimum interval of 2 months. The second dose is to be administered during the second year of life.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* According to country specific epidemiology.<br />&nbsp;</p><p><em>Booster</em></p><p>Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.</p><p><strong>&nbsp;</strong></p><p><em>Elderly</em></p><p>There are no data in individuals older than 65 years of age.</p><p>There are limited data in individuals aged 56-65 years.</p><p>&nbsp;</p><p><strong>Method of Administration</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_7e988f16-03d1-49ce-b34d-2b7021e50af5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Menveo is to be administered as an<strong><em> </em></strong>intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in children, adolescents and adults.</p><p>&nbsp;</p><p>Separate injection sites must be used if more than one vaccine is being administered at the same time.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see Use and Handling.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients of the vaccine, including diphtheria toxoid (CRM197) (see Formulation and Strength and Excipients). 

 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following administration of the vaccine.</p><p>&nbsp;</p><p>As with other vaccines, vaccination with Menveo should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection is not a contraindication.</p><p>&nbsp;</p><p>Anxiety‐related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection (see Adverse Reactions). It is important that procedures are in place to avoid injury from fainting.</p><p>Do not administer the vaccine intravascularly, subcutaneously or intradermally.<strong><em> </em></strong></p><p>&nbsp;</p><p>Menveo will not protect against infections caused by any other serogroups of <em>N. meningitidis</em> not present in the vaccine.</p><p>&nbsp;</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccines (see Pharmacodynamic effects).</p><p>&nbsp;</p><p>In immunocompromised individuals, vaccination may not result in an appropriate protective antibody response. Menveo has not been evaluated in the immunocompromised. Individuals with HIV infection, complement deficiencies and individuals with functional or anatomical asplenia may not mount an immune response to meningococcal group A, C, W-135 and Y conjugate vaccines.</p><p>&nbsp;</p><p>Individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) remain at increased risk of invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y even following vaccination with Menveo.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Only applicable to vial-syringe presentation</strong></p><p><strong>Latex-sensitive individuals</strong></p><p>The tip cap of the syringe may contain natural rubber latex (see Nature and contents of container).</p><p>Although the risk for developing allergic latex reactions is very small, healthcare professionals are encouraged to consider the benefit risk prior to administering this vaccine to patients with known history of hypersensitivity to latex.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Menveo can be given concomitantly with meningococcal group B vaccine (Bexsero).</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Children from 2 to 23 months of age</u></em></strong></p><p>Menveo can be given concomitantly with any of the following monovalent or combination vaccines: diphtheria, acellular pertussis, tetanus, <em>Haemophilus influenzae</em> type b (Hib), inactivated polio, hepatitis B (HBV), inactivated hepatitis A, 7-valent and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13), pentavalent rotavirus, and measles, mumps, rubella and varicella (MMRV). No increase in the reactogenicity or change in the safety profile of the routine vaccines was observed in clinical trials.</p><p><strong><s>&nbsp;</s></strong></p><p>No immune interference was observed for the concomitantly administered vaccines with exception of pneumococcal vaccine serotypes 6B and 19A post-dose 3.</p><p>No immune interference was observed post-dose 4 for any pneumococcal vaccine serotypes.<strong><s> </s></strong></p><p>&nbsp;</p><p><strong><em><u>Children from 2 to 10 years of age</u></em></strong></p><p>The safety and immunogenicity of other childhood vaccines when administered concomitantly with Menveo have not been evaluated.</p><p>&nbsp;</p><p><strong><em><u>Adolescents from 11 to 18 years of age</u></em></strong><strong><em><u> </u></em></strong></p><p>Menveo can be given concomitantly with any of the following monovalent or combination vaccines: tetanus, reduced diphtheria and acellular pertussis vaccine (dTpa) and human papillomavirus quadrivalent (Types 6, 11, 16 and 18) recombinant vaccine (HPV).</p><p>There was no evidence of increased reactogenicity, change in the safety profile, or impact on the antibody response of the vaccines following co-administration in clinical trials.</p><p>The sequential administration of Menveo one month after dTpa resulted in lower immune response for serogroup W-135 as measured by percentage of subjects with seroresponse. The clinical relevance of this observation is however unknown.</p><p>&nbsp;</p><p><strong><em><u>Adults</u></em></strong></p><p>Menveo can be given concomitantly with any of the following monovalent or combination vaccines: hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis and rabies.</p><p>No change in the safety profile of the vaccines was observed when co-administered with Menveo in clinical trials, and no clinically relevant interference was shown in the antibody response to the vaccines.</p><p>&nbsp;</p><p>Concomitant administration of Menveo and other vaccines than those listed above has not been studied. If Menveo is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.<strong><em>&nbsp; </em></strong></p><p>&nbsp;</p><p>If a vaccine recipient is undergoing immunosuppressant treatment, the immunological response may be diminished.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility </strong></p><p>Animal studies indicate no effects of Menveo on female fertility. Effects on male fertility have not been evaluated in animal studies.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p><strong>&nbsp;</strong></p><p>Insufficient clinical data on exposed pregnancies are available.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Animal studies with Menveo do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see Non-clinical information).</p><p>Menveo should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p><strong>&nbsp;</strong></p><p>Although insufficient clinical data on the use of Menveo during breast-feeding are available, it is unlikely that secreted antibodies in milk would be harmful when ingested by a breastfed infant. Therefore, Menveo may be used during breast feeding.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Menveo on the ability to drive and use machines have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical trial data</strong></p><p><strong>&nbsp;</strong></p><p>Adverse reactions reported are listed according to the following frequencies:</p><p>&nbsp;</p><p>Very common &ge; 1/10</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100 to &lt;1/10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/1,000 to &lt;1/100</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10,000 to &lt;1/1,000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p>&nbsp;</p><p><strong><em>Children from 2 to 23 months of age</em></strong></p><p>The safety of Menveo with 4-dose schedule was evaluated in three randomised, controlled multicenter clinical studies in which 8,735 infants 2 months of age at enrolment received Menveo concomitantly with routine paediatric vaccines (see <em>Interactions</em>). A total of 2,864 infants received the routine paediatric vaccines alone.</p><p><strong><em><s>&nbsp;</s></em></strong></p><p><em><u>Three-dose primary series</u></em></p><p>The safety of Menveo was assessed in 476 infants who completed a 3-dose infant series, including 297 who received doses at 2, 6 and 12 months and 179 who received doses at 2, 4 and 12 months of age.</p><p><em><u>Two-dose primary series</u></em></p><p>The safety of Menveo with 2-dose schedule was assessed in 2,180 children immunised between 6 and 23 months of age, in four randomised studies that addressed the safety of Menveo administered concomitantly with routine paediatric vaccines.</p><p><em><u>One-dose schedule</u></em></p><p>In three studies, the safety of one dose of Menveo when given concomitantly with routine paediatric vaccines in the second year of life was evaluated in 537 subjects.</p><p>&nbsp;</p><p><u>Metabolism and nutrition disorders:</u></p><p>Very common: eating disorder</p><p><u>&nbsp;</u></p><p><u>Nervous system disorders:</u></p><p>Very common: persistent crying, sleepiness</p><p><strong><u>&nbsp;</u></strong></p><p><u>Gastrointestinal disorders:</u></p><p>Very common: diarrhoea, vomiting</p><p><strong><u>&nbsp;</u></strong></p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Common: rash</p><p><u>&nbsp;</u></p><p><u>General disorders and administration site conditions:</u></p><p>Very common: irritability, injection site tenderness, injection site erythema (&le;50 mm), injection site induration (&le;50 mm)</p><p>Common: severe injection site tenderness, fever</p><p>Uncommon: injection site erythema (&gt;50 mm), injection site induration (&gt;50 mm)</p><p>&nbsp;</p><p><strong><em>Children from 2 to 10 years of age</em></strong></p><p>The characterisation of the safety profile of Menveo in children 2 to 10 years of age is based on data from 4 clinical trials in which 3,181 subjects received Menveo.&nbsp;</p><p>&nbsp;</p><p><u>Metabolism and nutrition disorders:</u></p><p>Common: eating disorder</p><p><u>&nbsp;</u></p><p><u>Nervous system disorders:</u></p><p>Very common: sleepiness, headache</p><p>&nbsp;</p><p><u>Gastrointestinal disorders:</u></p><p>Common: nausea, vomiting, diarrhoea</p><p><u>&nbsp;</u></p><p><u>Skin and subcutaneous tissue disorders:</u></p><p>Common: rash</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders:</u></p><p>Common: myalgia, arthralgia</p><p><u>&nbsp;</u></p><p><u>General disorders and administration site conditions:</u></p><p>Very common: irritability, malaise, injection site pain, injection site erythema (&le; 50 mm), injection site induration (&le; 50 mm)</p><p>Common: injection site erythema (&gt;50mm), injection site induration (&gt;50mm), chills, fever &ge;38<sup>o</sup>C</p><p>Uncommon: injection site pruritus</p><p><strong><em>Adolescents and adults from 11 to 65 years of age </em></strong></p><p><u>&nbsp;</u></p><p>The characterisation of the safety profile of Menveo in adolescents and adults is based on data from five randomised controlled clinical trials including 6,401 participants (from 11-65 years of age).</p><p>&nbsp;</p><p><u>Nervous system disorders</u>:</p><p>Very common: headache</p><p>Uncommon: dizziness</p><p><u>Gastrointestinal disorders</u>:</p><p>Very common: nausea</p><p><u>Skin and subcutaneous tissue disorders</u>:</p><p>Common: rash</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>Very common: myalgia</p><p>Common: arthralgia</p><p><u>General disorders and administration site conditions</u>:</p><p>Very common: injection site pain, injection site erythema (&le;50 mm), injection site induration (&le;50 mm), malaise</p><p>Common: injection site erythema (&gt;50 mm), injection site induration (&gt;50 mm), fever &ge;38&deg;C, chills</p><p>Uncommon: injection site pruritus</p><p>&nbsp;</p><p><strong>Post-marketing data</strong></p><p><strong>&nbsp;</strong></p><p>Because these events were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine exposure.</p><p><u>Blood and lymphatic system disorders</u><br />Local lymphadenopathy</p><p><u>&nbsp;</u></p><p><u>Immune system disorders</u><strong><em><u> </u></em></strong></p><p>Hypersensitivity including anaphylaxis</p><p><strong><s>&nbsp;</s></strong></p><p><u>Nervous system disorders</u></p><p>Dizziness, syncope, tonic convulsion, febrile convulsion, headache, facial paresis, balance disorder</p><p><strong><em>&nbsp;</em></strong></p><p><u>Eye disorders</u></p><p>Eyelid ptosis</p><p><strong><em>&nbsp;</em></strong></p><p><u>Ear and labyrinth disorders</u></p><p>Hearing impaired, ear pain, vertigo, vestibular disorder<strong><s> </s></strong></p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p>Oropharyngeal pain</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><u>Skin and subcutaneous tissue disorders</u><strong><em><u> </u></em></strong></p><p>Bullous conditions</p><p><strong><em>&nbsp;</em></strong></p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>Arthralgia, bone pain</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u><strong><em> </em></strong></p><p>Injection site pruritus, pain, erythema, inflammation and swelling, including extensive swelling of the injected limb, fatigue, malaise, pyrexia</p><p><strong><em>&nbsp;</em></strong></p><p><u>Investigations</u></p><p>Alanine aminotransferase increased</p><p><strong><em>&nbsp;</em></strong></p><p><u>Injury and poisoning and procedural complications</u></p><p>Fall, head injury.<strong><em><u> </u></em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting Hotline:19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/&nbsp;</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insufficient data are available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC code</strong></p><p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH08.</p><p><strong>Pharmacodynamic effects</strong><!--[if supportFields]><b><span
lang=EN-US style='font-family:"Arial",sans-serif;mso-fareast-font-family:"MS Mincho";
mso-ansi-language:EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d13ff5d9-8c4f-407f-aea6-e52444a9b87b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-US style='font-family:"Arial",sans-serif;mso-fareast-font-family:"MS Mincho";
mso-ansi-language:EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong><u>Clinical efficacy</u></strong></p><p>The efficacy of Menveo has been inferred by measuring the production of serogroup-specific anti-capsular antibodies with bactericidal activity. Serum bactericidal activity (SBA) was measured using human serum as the source of exogenous complement (hSBA).&nbsp; The hSBA was the original correlate of protection against meningococcal disease.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>Immunogenicity </u></strong></p><p>&nbsp;</p><p>Immunogenicity was evaluated in randomised, multicenter, active controlled clinical trials that enrolled persons from 2 months through 65 years of age.</p><p><u>&nbsp;</u></p><p><u>Immune responses following a 4-dose infant series (2 months through 16 months of age)</u></p><p><u>&nbsp;</u></p><p>The pre-specified endpoint for immunogenicity of Menveo in infants receiving a 4-dose series at 2, 4, 6 and 12 months of age was the proportion of subjects achieving an hSBA &ge; 1:8, with the lower limit of the 2-sided 95% CI for the point estimate being &ge; 80% of vaccinees for serogroup A, and &ge; 85% of vaccinees for serogroups C, W-135 and Y one month following the final dose.&nbsp;The immunogenicity of Menveo in infants was assessed in two pivotal randomised, controlled, multicenter studies of infants,<em> </em>who received a 4-dose series at 2, 4, 6 and 12 months of age and subjects who received a 4-dose series at 2, 4, 6, and 16 months of age.</p><p>&nbsp;</p><p>In two pivotal trials the pre-defined criteria for immunogenicity were met for all four serogroups A, C, W-135 and Y at one month following completion of a 4-dose series at 2, 4, 6 and 12 months (Table 1).</p><p>&nbsp;</p><p><strong>Table 1: Bactericidal antibody responses following administration of Menveo with routine paediatric vaccines at 2, 4, 6 and 12 or 16 months of age</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>2, 4, 6, 12 months of age</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>2, 4, 6, 16 months of age</strong></p></td></tr><tr><td rowspan="2"><p><strong>Serogroup</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study V59P14 &ndash; US subjects</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study V59_33 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study V59P14 &ndash;&nbsp; Latin America subjects</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Post<br />3<sup>rd</sup> dose</strong></p></td><td style="vertical-align:top"><p><strong>Post<br />4<sup>th</sup> dose</strong></p></td><td style="vertical-align:top"><p><strong>Post 3<sup>rd</sup> dose</strong></p></td><td style="vertical-align:top"><p><strong>Post<br />4<sup>th</sup> dose</strong></p></td><td style="vertical-align:top"><p><strong>Post 3<sup>rd</sup> dose</strong></p></td><td style="vertical-align:top"><p><strong>Post<br />4<sup>th</sup> dose</strong></p></td></tr></thead><tbody><tr><td rowspan="3"><p><strong>A</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N = 212</p></td><td style="vertical-align:top"><p>N = 84</p></td><td style="vertical-align:top"><p>N=202</p></td><td style="vertical-align:top"><p>N=168</p></td><td style="vertical-align:top"><p>N=268</p></td><td style="vertical-align:top"><p>N=120</p></td></tr><tr><td style="vertical-align:top"><p>(% &ge; <strong>1:8</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>67<br /><br />(61, 74)</p></td><td style="vertical-align:top"><p>94<br /><br />(87*, 98)</p></td><td style="vertical-align:top"><p>76<br /><br />(69, 81)</p></td><td style="vertical-align:top"><p>89<br /><br />(83*, 93)</p></td><td style="vertical-align:top"><p>89<br /><br />(85, 93)</p></td><td style="vertical-align:top"><p>95<br /><br />(89, 98)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>13<br /><br />(11, 16)</p></td><td style="vertical-align:top"><p>77<br /><br />(55, 109)</p></td><td style="vertical-align:top"><p>21<br /><br />(17, 26)</p></td><td style="vertical-align:top"><p>54<br /><br />(44, 67)</p></td><td style="vertical-align:top"><p>43<br /><br />(36, 52)</p></td><td style="vertical-align:top"><p>146<br /><br />(113, 188)</p></td></tr><tr><td rowspan="3"><p><strong>C</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N = 204</p></td><td style="vertical-align:top"><p>N = 86</p></td><td style="vertical-align:top"><p>N=199</p></td><td style="vertical-align:top"><p>N=156</p></td><td style="vertical-align:top"><p>N=272</p></td><td style="vertical-align:top"><p>N=122</p></td></tr><tr><td style="vertical-align:top"><p>(% &ge; <strong>1:8</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>97<br /><br />(93, 99)</p></td><td style="vertical-align:top"><p>98<br /><br />(92*, 100)</p></td><td style="vertical-align:top"><p>94<br /><br />(90, 97)</p></td><td style="vertical-align:top"><p>95<br /><br />(90*, 98)</p></td><td style="vertical-align:top"><p>97<br /><br />(94, 99)</p></td><td style="vertical-align:top"><p>98<br /><br />(94, 100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>108<br />&nbsp;</p><p>(92, 127)</p></td><td style="vertical-align:top"><p>227<br />&nbsp;</p><p>155, 332)</p></td><td style="vertical-align:top"><p>74<br />&nbsp;</p><p>(62, 87)</p></td><td style="vertical-align:top"><p>135<br />&nbsp;</p><p>(107, 171)</p></td><td style="vertical-align:top"><p>150<br />&nbsp;</p><p>(127, 177)</p></td><td style="vertical-align:top"><p>283<br />&nbsp;</p><p>(225, 355)</p></td></tr><tr><td rowspan="3"><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N = 197</p></td><td style="vertical-align:top"><p>N = 85</p></td><td style="vertical-align:top"><p>N=194</p></td><td style="vertical-align:top"><p>N=153</p></td><td style="vertical-align:top"><p>N=264</p></td><td style="vertical-align:top"><p>N=112</p></td></tr><tr><td style="vertical-align:top"><p>(% &ge; <strong>1:8</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>96<br /><br />(93, 99)</p></td><td style="vertical-align:top"><p>100<br /><br />(96*, 100)</p></td><td style="vertical-align:top"><p>98<br /><br />(95, 99)</p></td><td style="vertical-align:top"><p>97<br /><br />(93*, 99)</p></td><td style="vertical-align:top"><p>98<br /><br />(96,100)</p></td><td style="vertical-align:top"><p>100<br /><br />(97, 100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>100<br />&nbsp;</p><p>(86, 116)</p></td><td style="vertical-align:top"><p>416<br />&nbsp;</p><p>(288, 602)</p></td><td style="vertical-align:top"><p>79<br />&nbsp;</p><p>(67, 92)</p></td><td style="vertical-align:top"><p>215<br />&nbsp;</p><p>(167, 227)</p></td><td style="vertical-align:top"><p>182<br />&nbsp;</p><p>(159, 208)</p></td><td style="vertical-align:top"><p>727<br />&nbsp;</p><p>(586, 903)</p></td></tr><tr><td rowspan="3"><p><strong>Y</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N = 182</p></td><td style="vertical-align:top"><p>N = 84</p></td><td style="vertical-align:top"><p>N=188</p></td><td style="vertical-align:top"><p>N=153</p></td><td style="vertical-align:top"><p>N=263</p></td><td style="vertical-align:top"><p>N=109</p></td></tr><tr><td style="vertical-align:top"><p>(% &ge; <strong>1:8</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>96<br /><br />(92, 98)</p></td><td style="vertical-align:top"><p>100<br /><br />(96*, 100)</p></td><td style="vertical-align:top"><p>94<br /><br />(89, 97)</p></td><td style="vertical-align:top"><p>96<br /><br />(92*, 99)</p></td><td style="vertical-align:top"><p>98<br /><br />(96, 99)</p></td><td style="vertical-align:top"><p>99<br /><br />(95, 100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GMT</strong></p><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>73</p><p>(62, 86)</p></td><td style="vertical-align:top"><p>395</p><p>(269, 580)</p></td><td style="vertical-align:top"><p>51</p><p>(43, 61)</p></td><td style="vertical-align:top"><p>185</p><p>(148, 233)</p></td><td style="vertical-align:top"><p>125</p><p>(107, 146)</p></td><td style="vertical-align:top"><p>590</p><p>(463, 751)</p></td></tr></tbody></table><p>* Prespecified criteria for adequacy of immune response were met (Study V59P14, US cohort: lower limit (LL) of 95% CI) &ge; 80% for serogroup A and &ge; 85% for serogroups C, W-135, and Y; Study V59_33: LL of the 95% CI &gt; 80% for serogroup A and &gt; 85% for serogroups C, W, and Y).<br />Serum Bactericidal Assay with exogenous human complement source (hSBA).&nbsp;</p><p>%&ge;1:8&nbsp; = proportions of subjects with hSBA &ge; 1:8 against a given serogroup; CI = confidence interval; GMT = geometric mean antibody titre; N = number of infants eligible for inclusion in the Per-Protocol Immunogenicity population for whom serological results were available for the post-dose 3 and post-dose 4 evaluations.</p><p>In a separate study performed in Canada in 90 infants receiving Menveo concomitantly with&nbsp; diphtheria toxoid, acellular pertussis, tetanus toxoid, inactivated polio types 1, 2 and 3, <em>Haemophilus influenzae</em>&nbsp; type b (Hib), and 7-valent pneumococcal conjugate vaccine, the percentages of subjects with hSBA &ge; 1:8 were 49% for serogroup A, 89% for serogroup C, 92% for serogroup W-135 and 86% for serogroup Y at one month after the second dose of the infant vaccination series (doses administered at 2 and 4 months of age).</p><p><u>Immune responses following a 3-dose infant series (2 months through 12 months of age)</u><strong><em><s> </s></em></strong><em>(applicable if the three-dose primary infants schedule is included in the country submission)</em></p><p>In study V59_36, children 2 months of age at enrolment were administered either 4 doses at 2, 4, 6 and 12 months of age or 3 doses at 2, 4 and 12 months of age. By one month after the second vaccination (5 months of age), substantial increases in immune responses were seen for all 4 serogroups. The 3-dose series was shown to be non-inferior to the 4-dose series for serogroups C, W-135 and Y at 1 month after the 12 month vaccination.&nbsp; The hSBA GMTs at 13 months were also similar between the 3-dose and 4-dose groups for serogroups C, W-135 and Y (Table 2). Non-inferiority for serogroup A was not assessed.</p><p><strong>Table 2: Bactericidal antibody responses following a 3-dose (2, 4 and 12 months) and a 4-dose infant series of Menveo with routine paediatric vaccines</strong></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Serogroup</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Percentages of Subjects with hSBA &ge;1:8</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>hSBA GMTs</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Menveo 3-dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Menveo 4-dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Menveo 3-dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Menveo 4-dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>5 months</p></td><td style="vertical-align:top"><p>13 months</p></td><td style="vertical-align:top"><p>7 months</p></td><td style="vertical-align:top"><p>13 months</p></td><td style="vertical-align:top"><p>5 months</p></td><td style="vertical-align:top"><p>13 months</p></td><td style="vertical-align:top"><p>7 months</p></td><td style="vertical-align:top"><p>13 months</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>A</p></td><td style="vertical-align:top"><p>N=157<br />&nbsp;</p></td><td style="vertical-align:top"><p>N=146</p></td><td style="vertical-align:top"><p>N=157</p></td><td style="vertical-align:top"><p>N=141</p></td><td style="vertical-align:top"><p>N=157</p></td><td style="vertical-align:top"><p>N=146</p></td><td style="vertical-align:top"><p>N=157</p></td><td style="vertical-align:top"><p>N=141</p></td></tr><tr><td style="vertical-align:top"><p>43<br />&nbsp;</p><p>(35-51)</p></td><td style="vertical-align:top"><p>88<br /><br />(82-93)</p></td><td style="vertical-align:top"><p>84<br />&nbsp;</p><p>(77-89)</p></td><td style="vertical-align:top"><p>96<br /><br />(91-98)</p></td><td style="vertical-align:top"><p>7.09<br />&nbsp;</p><p>(5.62-8.94)</p></td><td style="vertical-align:top"><p>59<br /><br />(45-77)</p></td><td style="vertical-align:top"><p>28<br />&nbsp;</p><p>(23-35)</p></td><td style="vertical-align:top"><p>94<br /><br />(76-117)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>C</p></td><td style="vertical-align:top"><p>N=170</p></td><td style="vertical-align:top"><p>N=160</p></td><td style="vertical-align:top"><p>N=176</p></td><td style="vertical-align:top"><p>N=152</p></td><td style="vertical-align:top"><p>N=170</p></td><td style="vertical-align:top"><p>N=160</p></td><td style="vertical-align:top"><p>N=176</p></td><td style="vertical-align:top"><p>N=152</p></td></tr><tr><td style="vertical-align:top"><p>86<br />&nbsp;</p><p>(80-91)</p></td><td style="vertical-align:top"><p>95*<br /><br />(90-98)</p></td><td style="vertical-align:top"><p>95<br />&nbsp;</p><p>(91-98)</p></td><td style="vertical-align:top"><p>99<br />&nbsp;</p><p>(95-100)</p></td><td style="vertical-align:top"><p>50<br />&nbsp;</p><p>(39-64)</p></td><td style="vertical-align:top"><p>124<br /><br />(99-156)</p></td><td style="vertical-align:top"><p>86<br />&nbsp;</p><p>(70-104)</p></td><td style="vertical-align:top"><p>160<br /><br />(130-198)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>W-135</p></td><td style="vertical-align:top"><p>N=162</p></td><td style="vertical-align:top"><p>N=153</p></td><td style="vertical-align:top"><p>N=162</p></td><td style="vertical-align:top"><p>N=138</p></td><td style="vertical-align:top"><p>N=162</p></td><td style="vertical-align:top"><p>N=153</p></td><td style="vertical-align:top"><p>N=162</p></td><td style="vertical-align:top"><p>N=138</p></td></tr><tr><td style="vertical-align:top"><p>86<br />&nbsp;</p><p>(80-91)</p></td><td style="vertical-align:top"><p>99*<br /><br />(96-100)</p></td><td style="vertical-align:top"><p>99<br />&nbsp;</p><p>(96-100)</p></td><td style="vertical-align:top"><p>99<br /><br />(96-100)</p></td><td style="vertical-align:top"><p>55<br />&nbsp;</p><p>(42-71)</p></td><td style="vertical-align:top"><p>248<br /><br />(202-303)</p></td><td style="vertical-align:top"><p>90<br />&nbsp;</p><p>(77-104)</p></td><td style="vertical-align:top"><p>244<br /><br />(195-305)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Y</p></td><td style="vertical-align:top"><p>N=152</p></td><td style="vertical-align:top"><p>N=154</p></td><td style="vertical-align:top"><p>N=163</p></td><td style="vertical-align:top"><p>N=146</p></td><td style="vertical-align:top"><p>N=152</p></td><td style="vertical-align:top"><p>N=154</p></td><td style="vertical-align:top"><p>N=163</p></td><td style="vertical-align:top"><p>N=146</p></td></tr><tr><td style="vertical-align:top"><p>67<br />&nbsp;</p><p>(59-75)</p></td><td style="vertical-align:top"><p>100*<br /><br />(98-100)</p></td><td style="vertical-align:top"><p>94<br />&nbsp;</p><p>(90-97)</p></td><td style="vertical-align:top"><p>99<br /><br />(96-100)</p></td><td style="vertical-align:top"><p>20<br />&nbsp;</p><p>(15-26)</p></td><td style="vertical-align:top"><p>212<br /><br />(175-258)</p></td><td style="vertical-align:top"><p>52<br />&nbsp;</p><p>(43-64)</p></td><td style="vertical-align:top"><p>254<br /><br />(203-318)</p></td></tr></tbody></table><p>* Non-inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [3-dose series minus 4-dose series].</p><p>In study V59P14, children 2 months of age at enrolment were administered either 3 doses at 2, 6 and 12 months of age or 4 doses at 2, 4, 6 and 18 months of age, and were assessed for immune response at 7 months of age.&nbsp; Among 284 infants who received doses at 2 and 6 months, 74%, 94%, 99%, 97% had hSBA &ge; 1:8 against serogroups A, C, W-135 and Y, respectively, compared to 89%, 97%, 98%, and 98% of&nbsp; 277 infants who received doses at 2, 4, and 6 months.&nbsp; Pre-specified non-inferiority criteria were met for serogroups C, W-135, and Y.</p><p><u>Immune responses following a 2-dose series in children 6 months through 23 months of age</u></p><p>&nbsp;</p><p>The immunogenicity of Menveo was assessed in children, who did not receive the 4-dose series but instead received 2 dose series. Among the per protocol population of 386 subjects, after Menveo administered at 7-9 and at 12 months, the proportions of subjects with hSBA &ge; 1:8 for serogroups A, C, W-135, and Y were respectively: 88% (84-91), 100% (98-100), 98% (96-100), 96% (93-99).&nbsp;</p><p>&nbsp;</p><p>A 2-dose series was also examined in a study of Latin American children, who received Menveo at 12 and 16 months of age.&nbsp; Among the per protocol population of 106 subjects, the proportions of subjects with hSBA &ge;1:8 for serogroups A, C, W-135 and Y were 97% (92-99), 100% (96-100), 100% (96-100), and 100% (96-100), respectively.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity in children (2-10 years of age)</u></p><p><u>&nbsp;</u></p><p>In the pivotal study V59P20 immunogenicity of Menveo was compared to quadrivalent diphtheria toxoid conjugate meningococcal vaccine (ACWY-D); 1,170 children were vaccinated with Menveo and 1,161 received the comparator vaccine in the per protocol populations.&nbsp; In two supportive studies V59P8 and V59P10 immunogenicity of Menveo was compared to quadrivalent meningococcal polysaccharide vaccine (ACWY-PS).&nbsp;</p><p>&nbsp;</p><p>In the pivotal, randomised, observer-blind study V59P20, in which participants were stratified by age (2 through 5 years and 6 through 10 years), the immunogenicity of a single dose of Menveo one month post-vaccination was compared with the single dose of ACWY-D.&nbsp; In both age groups, non-inferiority of Menveo to ACWY-D for the proportion of subjects with a seroresponse and percentage of subjects with hSBA &ge;1:8 was demonstrated for serogroups C, W-135 and Y, but not for serogroup A.&nbsp; For both age groups (2-5 years and 6-10 years of age), the immune response as measured by hSBA GMTs was non-inferior for all serogroups (Table 3). In addition, the percentage of subjects with a seroresponse, percentage of subjects with hSBA &ge;1:8, and GMT levels were statistically higher among Menveo recipients for serogroups W-135 and Y.&nbsp; GMT levels were also statistically higher among Menveo recipients for serogroup C.</p><p>&nbsp;</p><p><strong>Table 3: Comparison of serum bactericidal antibody responses to Menveo and ACWY-D 1 month after vaccination of subjects 2 through 10 years of age</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:111%"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="3"><p><strong>2-5 years </strong></p></td><td colspan="3"><p><strong>6-10 years </strong></p></td><td colspan="3"><p><strong>2-10 years </strong></p></td></tr><tr><td><p><strong>Endpoint by Serogroup</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-D </strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Percent Difference (Menveo &ndash; ACWY-D) or GMT ratio (Menveo/ ACWY-D)</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-D </strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Percent Difference (Menveo &ndash; ACWY-D) or GMT ratio (Menveo/ ACWY-D)</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-D </strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Percent Difference (Menveo &ndash; ACWY-D) or GMT ratio (Menveo/ ACWY-D)</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p><strong>A</strong></p></td><td style="vertical-align:top"><p>N=606</p></td><td style="vertical-align:top"><p>N=611</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=551</p></td><td style="vertical-align:top"><p>N=541</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=1157</p></td><td style="vertical-align:top"><p>N=1152</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td style="vertical-align:top"><p>72<br /><br />(68, 75)</p></td><td style="vertical-align:top"><p>77<br /><br />(73, 80)</p></td><td style="vertical-align:top"><p>-5<br /><br />(-10.0, -0.3)</p></td><td style="vertical-align:top"><p>77<br /><br />(73, 80)</p></td><td style="vertical-align:top"><p>83<br /><br />(79, 86)</p></td><td style="vertical-align:top"><p>-6<br /><br />(-11, -1)</p></td><td style="vertical-align:top"><p>74<br /><br />(71, 76)</p></td><td style="vertical-align:top"><p>80<br /><br />(77, 82)</p></td><td style="vertical-align:top"><p>-6*<br /><br />(-9, -2)</p></td></tr><tr><td><p>%&ge; 1:8</p></td><td style="vertical-align:top"><p>72<br /><br />(68, 75)</p></td><td style="vertical-align:top"><p>78<br /><br />(74, 81)</p></td><td style="vertical-align:top"><p>-6<br /><br />(-11, -1)</p></td><td style="vertical-align:top"><p>77<br /><br />(74, 81)</p></td><td style="vertical-align:top"><p>83<br /><br />(80, 86)</p></td><td style="vertical-align:top"><p>-6<br /><br />(-11, -1)</p></td><td style="vertical-align:top"><p>&nbsp;75<br /><br />(72, 77)</p></td><td style="vertical-align:top"><p>&nbsp;80<br /><br />(78, 83)</p></td><td style="vertical-align:top"><p>-6*<br /><br />(-9,-3)</p></td></tr><tr><td><p>GMT</p></td><td style="vertical-align:top"><p>26<br /><br />(22, 30)</p></td><td style="vertical-align:top"><p>25<br /><br />(21, 29)</p></td><td style="vertical-align:top"><p>1.04*<br /><br />(0.86, 1.27)</p></td><td style="vertical-align:top"><p>35<br /><br />(29, 42)</p></td><td style="vertical-align:top"><p>35<br /><br />(29, 41)</p></td><td style="vertical-align:top"><p>1.01*<br /><br />(0.83, 1.24)</p></td><td style="vertical-align:top"><p>30<br /><br />(27, 34)</p></td><td style="vertical-align:top"><p>29<br /><br />(26, 33)</p></td><td style="vertical-align:top"><p>1.03*<br /><br />(0.89,1.18)</p></td></tr><tr><td><p><strong>C</strong></p></td><td style="vertical-align:top"><p>N=607</p></td><td style="vertical-align:top"><p>N=615</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=554</p></td><td style="vertical-align:top"><p>N=539</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=1161</p></td><td style="vertical-align:top"><p>N=1154</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td style="vertical-align:top"><p>60<br /><br />(56, 64)</p></td><td style="vertical-align:top"><p>56<br /><br />(52, 60)</p></td><td style="vertical-align:top"><p>4 *<br /><br />(-2, 9)</p></td><td style="vertical-align:top"><p>63<br /><br />(59, 67)</p></td><td style="vertical-align:top"><p>57<br /><br />(53, 62)</p></td><td style="vertical-align:top"><p>6*<br /><br />(0, 11)</p></td><td style="vertical-align:top"><p>61<br /><br />(58, 64)</p></td><td style="vertical-align:top"><p>57<br /><br />(54, 60)</p></td><td style="vertical-align:top"><p>5* <sup>&sect;</sup><br /><br />(1, 9)</p></td></tr><tr><td><p>%&ge; 1:8</p></td><td style="vertical-align:top"><p>68<br /><br />(64, 72)</p></td><td style="vertical-align:top"><p>64<br /><br />(60, 68)</p></td><td style="vertical-align:top"><p>4*<br /><br />(-1, 10)</p></td><td style="vertical-align:top"><p>77<br /><br />(73, 80)</p></td><td style="vertical-align:top"><p>74<br /><br />(70, 77)</p></td><td style="vertical-align:top"><p>3*<br />&nbsp;<br />(-2, 8)</p></td><td style="vertical-align:top"><p>72<br /><br />(70, 75)</p></td><td style="vertical-align:top"><p>68<br /><br />(66, 71)</p></td><td style="vertical-align:top"><p>4*<br /><br />(0, 8)</p></td></tr><tr><td><p>GMT</p></td><td style="vertical-align:top"><p>18<br /><br />(15, 20)</p></td><td style="vertical-align:top"><p>13<br /><br />(11, 15)</p></td><td style="vertical-align:top"><p>1.33* <sup>&sect;</sup><br />&nbsp;<br />(1.11, 1.6)</p></td><td style="vertical-align:top"><p>36<br /><br />(29, 45)</p></td><td style="vertical-align:top"><p>27<br /><br />(21, 33)</p></td><td style="vertical-align:top"><p>1.36* <sup>&sect;</sup><br /><br />(1.06, 1.73)</p></td><td style="vertical-align:top"><p>23<br /><br />(21, 27)</p></td><td style="vertical-align:top"><p>17<br /><br />(15, 20)</p></td><td style="vertical-align:top"><p>1.34* <sup>&sect;</sup><br /><br />(1.15, 1.56)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p>N=594</p></td><td style="vertical-align:top"><p>N=605</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=542</p></td><td style="vertical-align:top"><p>N=533</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=1136</p></td><td style="vertical-align:top"><p>N=1138</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td style="vertical-align:top"><p>72<br /><br />(68, 75)</p></td><td style="vertical-align:top"><p>58<br /><br />(54, 62)</p></td><td style="vertical-align:top"><p>14 * <sup>&sect;</sup><br /><br />(9, 19)</p></td><td style="vertical-align:top"><p>57<br /><br />(53, 61)</p></td><td style="vertical-align:top"><p>44<br /><br />(40, 49)</p></td><td style="vertical-align:top"><p>13* <sup>&sect;</sup><br /><br />(7, 18)</p></td><td style="vertical-align:top"><p>65<br /><br />(62, 67)</p></td><td style="vertical-align:top"><p>51<br /><br />(48, 54)</p></td><td style="vertical-align:top"><p>13* <sup>&sect;</sup><br /><br />(9, 17)</p></td></tr><tr><td><p>%&ge;1:8</p></td><td style="vertical-align:top"><p>90<br /><br />(87, 92)</p></td><td style="vertical-align:top"><p>75<br /><br />(71, 78)</p></td><td style="vertical-align:top"><p>15* <sup>&sect;</sup><br /><br />(11, 19)</p></td><td style="vertical-align:top"><p>91<br /><br />(88, 93)</p></td><td style="vertical-align:top"><p>84<br /><br />(81, 87)</p></td><td style="vertical-align:top"><p>7* <sup>&sect;</sup><br /><br />(3, 11)</p></td><td style="vertical-align:top"><p>&nbsp;90<br /><br />(88, 92)</p></td><td style="vertical-align:top"><p>&nbsp;79<br /><br />(77, 81)</p></td><td style="vertical-align:top"><p>11* <sup>&sect;</sup><br /><br />(8, 14)</p></td></tr><tr><td><p>GMT</p></td><td style="vertical-align:top"><p>43<br /><br />(38, 50)</p></td><td style="vertical-align:top"><p>21<br /><br />(19, 25)</p></td><td style="vertical-align:top"><p>2.02* <sup>&sect;</sup><br /><br />(1.71, 2.39)</p></td><td style="vertical-align:top"><p>61<br /><br />(52, 72)</p></td><td style="vertical-align:top"><p>35<br /><br />(30, 42)</p></td><td style="vertical-align:top"><p>1.72* <sup>&sect;</sup><br /><br />(1.44, 2.06)</p></td><td style="vertical-align:top"><p>49<br /><br />(44, 54)</p></td><td style="vertical-align:top"><p>26<br /><br />(23, 29)</p></td><td style="vertical-align:top"><p>1.87* <sup>&sect;</sup><br /><br />(1.65, 2.12)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td style="vertical-align:top"><p>N=593</p></td><td style="vertical-align:top"><p>N=600</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=545</p></td><td style="vertical-align:top"><p>N=539</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=1138</p></td><td style="vertical-align:top"><p>N=1139</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td style="vertical-align:top"><p>66<br /><br />(62, 70)</p></td><td style="vertical-align:top"><p>45<br /><br />(41, 49)</p></td><td style="vertical-align:top"><p>21 * <sup>&sect;</sup><br /><br />(16, 27)</p></td><td style="vertical-align:top"><p>58<br /><br />(54, 62)</p></td><td style="vertical-align:top"><p>39<br /><br />(35, 44)</p></td><td style="vertical-align:top"><p>19* <sup>&sect;</sup><br /><br />(13, 24)</p></td><td style="vertical-align:top"><p>62<br /><br />(60, 65)</p></td><td style="vertical-align:top"><p>42<br /><br />(40, 45)</p></td><td style="vertical-align:top"><p>20* <sup>&sect;</sup><br /><br />(16, 24)</p></td></tr><tr><td><p>%&ge;1:8</p></td><td style="vertical-align:top"><p>76<br /><br />(72, 79)</p></td><td style="vertical-align:top"><p>57<br /><br />(53, 61)</p></td><td style="vertical-align:top"><p>19* <sup>&sect;</sup><br /><br />(14, 24)</p></td><td style="vertical-align:top"><p>79<br /><br />(76, 83)</p></td><td style="vertical-align:top"><p>63<br /><br />(59, 67)</p></td><td style="vertical-align:top"><p>16* <sup>&sect;</sup><br /><br />(11, 21)</p></td><td style="vertical-align:top"><p>&nbsp;77<br /><br />(75, 80)</p></td><td style="vertical-align:top"><p>&nbsp;60<br /><br />(57, 63)</p></td><td style="vertical-align:top"><p>18* <sup>&sect;</sup><br /><br />(14, 21)</p></td></tr><tr><td><p>GMT</p></td><td style="vertical-align:top"><p>24<br /><br />(20, 28)</p></td><td style="vertical-align:top"><p>10<br /><br />(8.68, 12)</p></td><td style="vertical-align:top"><p>2.36* <sup>&sect;</sup><br /><br />(1.95, 2.85)</p></td><td style="vertical-align:top"><p>34<br /><br />(28, 41)</p></td><td style="vertical-align:top"><p>14<br /><br />(12, 17)</p></td><td style="vertical-align:top"><p>2.41* <sup>&sect;</sup><br /><br />(1.95, 2.97)</p></td><td style="vertical-align:top"><p>29<br /><br />(25, 32)</p></td><td style="vertical-align:top"><p>12<br /><br />(11, 14)</p></td><td style="vertical-align:top"><p>2.37* <sup>&sect;</sup><br /><br />(2.06, 2.73)</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>* Non-inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-D] and &gt; 0.5 for ratio of GMTs [Menveo/ACWY-D]).</p><p>&sect; Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known</p><p>&nbsp;</p><p><em>The following paragraph can be included when the indication for this age group follows the US label (two doses for all children at continued high risk):<strong> </strong></em></p><p><em>&nbsp;</em></p><p>In the same study, a separate group of children, 2 through 5 years of age (N=297) in the per protocol population were immunized with two doses of Menveo, two months apart. The observed seroresponse rates (with 95% CI) at 1 month after the second dose were: 91% (87-94), 98% (95-99), 89% (85-92), and 95% (91-97) for serogroups A, C, W-135 and Y, respectively.&nbsp; The proportion of subjects with hSBA &ge; 1:8 (95% CI) were 91% (88-94), 99% (97-100), 99% (98-100), and 98% (95-99) for serogroups A, C, W-135 and Y, respectively.&nbsp; The hSBA GMTs (95% CI) for this group were 64 (51-81), 144 (118-177), 132 (111-157), and 102 (82-126) for serogroups A, C, W-135 and Y, respectively.</p><p>&nbsp;</p><p>In another randomised, observer-blind study (V59P8) US children were immunised with a single dose of either Menveo (N=284) or ACWY-PS (N=285). In the children 2-10 years of age, as well as in each age strata (2-5 and 6-10 years), immune response as measured by percentage of subjects with seroresponse, hSBA&ge;1:8 and GMTs were not only non-inferior to comparator vaccine ACWY-PS, but all were statistically higher than the comparator for all serogroups and all immune measurements at 1 month post-vaccination (Table 4).&nbsp;</p><p>&nbsp;</p><p><strong>Table 4: Comparison of serum bactericidal antibody responses to Menveo and ACWY-PS 1 month and 12 months after vaccination of subjects 2 through 10 years of age</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td><p><strong>Endpoint by Serogroup</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Percent Difference (Menveo &ndash; ACWY-PS)&nbsp; or</strong></p><p><strong>GMT ratio (Menveo/ACWY-PS)(95% CI)</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Percent Difference (Menveo &ndash; ACWY-PS)&nbsp; or</strong></p><p><strong>GMT ratio (Menveo/ACWY-PS)(95% CI)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>1 month post-vaccination</p></td><td colspan="3" style="vertical-align:top"><p>12 months post-vaccination</p></td></tr><tr><td><p><strong>A</strong></p></td><td style="vertical-align:top"><p>N=280</p></td><td style="vertical-align:top"><p>N=281</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=253</p></td><td style="vertical-align:top"><p>N=238</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Seroresponse&Dagger;</p></td><td><p>79<br />&nbsp;</p><p>(74, 84)</p></td><td><p>37<br />&nbsp;</p><p>(31, 43)</p></td><td><p>43 *&sect;<br />&nbsp;</p><p>(35, 50)</p></td><td><p>n/a</p></td><td><p>n/a</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>%&ge;1:8</p></td><td><p>79<br />&nbsp;</p><p>(74, 84)</p></td><td><p>37<br />&nbsp;</p><p>(31, 43)</p></td><td><p>42 *&sect;<br />&nbsp;</p><p>(35, 49)</p></td><td><p>23<br />&nbsp;</p><p>(18, 29)</p></td><td><p>13<br />&nbsp;</p><p>(9, 18)</p></td><td><p>10 *&sect;<br />&nbsp;</p><p>(3, 17)</p></td></tr><tr><td><p>GMT</p></td><td><p>36<br />&nbsp;</p><p>(30, 44)</p></td><td><p>6.31<br />&nbsp;</p><p>(5.21, 7.64)</p></td><td><p>5.74*&sect;<br />&nbsp;</p><p>(4.38, 7.53)</p></td><td><p>3.88<br />&nbsp;</p><p>(3.39, 4.44)</p></td><td><p>3<br />&nbsp;</p><p>&nbsp;(2.61, 3.44)</p></td><td><p>1.29 *&sect;<br />&nbsp;</p><p>(1.07, 1.57)</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p>N=281</p></td><td><p>N=283</p></td><td><p>&nbsp;</p></td><td><p>N=252</p></td><td><p>N=240</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Seroresponse&Dagger;</p></td><td><p>64<br />&nbsp;</p><p>(59, 70)</p></td><td><p>43<br />&nbsp;</p><p>(38, 49)</p></td><td><p>21*&sect;<br />&nbsp;</p><p>(13, 29)</p></td><td><p>n/a</p></td><td><p>n/a</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>%&ge;1:8</p></td><td><p>73<br />&nbsp;</p><p>(68, 78)</p></td><td><p>54<br />&nbsp;</p><p>&nbsp;(48, 60)</p></td><td><p>19 *&sect;<br />&nbsp;</p><p>(11, 27)</p></td><td><p>53<br />&nbsp;</p><p>(47, 59)</p></td><td><p>44<br />&nbsp;</p><p>(38, 51)</p></td><td><p>9 *<br />&nbsp;</p><p>(0, 18)</p></td></tr><tr><td><p>GMT</p></td><td><p>26<br />&nbsp;</p><p>(21, 34)</p></td><td><p>15<br />&nbsp;</p><p>(12, 20)</p></td><td><p>1.71*&sect;<br />&nbsp;</p><p>(1.22, 2.40)</p></td><td><p>11<br />&nbsp;</p><p>(8.64, 13)</p></td><td><p>9.02<br />&nbsp;</p><p>(7.23, 11)</p></td><td><p>1.19*<br />&nbsp;</p><p>(0.87, 1.62)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=279</p></td><td><p>N=282</p></td><td><p>&nbsp;</p></td><td><p>N=249</p></td><td><p>N=237</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Seroresponse&Dagger;</p></td><td><p>67<br />&nbsp;</p><p>(61, 72)</p></td><td><p>31<br />&nbsp;</p><p>(26, 37)</p></td><td><p>35 *&sect;<br />&nbsp;</p><p>(28, 43)</p></td><td><p>n/a</p></td><td><p>n/a</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>%&ge;1:8</p></td><td><p>92<br />&nbsp;</p><p>(88, 95)</p></td><td><p>66<br />&nbsp;</p><p>&nbsp;(60, 71)</p></td><td><p>26 *&sect;<br />&nbsp;</p><p>(20, 33)</p></td><td><p>90<br />&nbsp;</p><p>(86, 94)</p></td><td><p>45<br />&nbsp;</p><p>(38, 51)</p></td><td><p>46 *&sect;<br />&nbsp;</p><p>(38, 53)</p></td></tr><tr><td><p>GMT</p></td><td><p>60<br />&nbsp;</p><p>(50, 71)</p></td><td><p>14<br />&nbsp;</p><p>(12, 17)</p></td><td><p>4.26*&sect;<br />&nbsp;</p><p>&nbsp;(3.35, 5.43)</p></td><td><p>42<br />&nbsp;</p><p>&nbsp;(35, 50)</p></td><td><p>7.57<br />&nbsp;</p><p>(6.33, 9.07)</p></td><td><p>5.56 *&sect;<br />&nbsp;</p><p>(4.32, 7.15)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=280</p></td><td><p>N=282</p></td><td><p>&nbsp;</p></td><td><p>N=250</p></td><td><p>N=239</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Seroresponse&Dagger;</p></td><td><p>75<br />&nbsp;</p><p>(70, 80)</p></td><td><p>38<br />&nbsp;</p><p>(32, 44)</p></td><td><p>37 *&sect;<br />&nbsp;</p><p>(30, 45)</p></td><td><p>n/a</p></td><td><p>n/a</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>%&ge;1:8</p></td><td><p>88<br />&nbsp;</p><p>&nbsp;(83, 91)</p></td><td><p>53<br />&nbsp;</p><p>(47, 59)</p></td><td><p>34*&sect;<br />&nbsp;</p><p>&nbsp;(27, 41)</p></td><td><p>77<br />&nbsp;</p><p>(71, 82)</p></td><td><p>32<br />&nbsp;</p><p>(26, 38)</p></td><td><p>45 *&sect;<br />&nbsp;</p><p>(37, 53)</p></td></tr><tr><td><p>GMT</p></td><td><p>54<br />&nbsp;</p><p>(44, 66)</p></td><td><p>11<br />&nbsp;</p><p>(9.29, 14)</p></td><td><p>4.70 *&sect;<br />&nbsp;</p><p>(3.49, 6.31)</p></td><td><p>27<br />&nbsp;</p><p>(22, 33)</p></td><td><p>5.29<br /><br />(4.34, 6.45)</p></td><td><p>5.12 *&sect;<br />&nbsp;</p><p>(3.88, 6.76)</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>* Non-inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-PS] and &gt; 0.5 for ratio of GMTs [Menveo/ACWY-PS]).</p><p>&sect; Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known.</p><p>n/a = not applicable</p><p>&nbsp;</p><p>In a randomised, observer-blind study (V59P10) conducted in Argentina, children were immunised with a single dose of either Menveo (N=949) or ACWY-PS (N=551). Immunogenicity was assessed in a subset of 150 subjects in each vaccine group.&nbsp; The immune response observed in the children 2-10 years of age was very similar to those observed in the V59P8 study shown above:&nbsp; immune response to Menveo at 1 month post-vaccination, as measured by percentage of subjects with seroresponse, hSBA&ge;1:8 and GMTs, was non-inferior to ACWY-PS.&nbsp;</p><p>&nbsp;</p><p><em><u>Persistence of immune response and booster response in children (2-10 years of age)</u></em></p><p>&nbsp;</p><p>Persistence of immune response 1 year after primary vaccination with Menveo was evaluated in study V59P8. At 1 year post-vaccination, Menveo continued to be statistically higher than ACWY-PS for serogroups A, W-135 and Y, as measured by percentage of subjects with hSBA&ge;1:8 and GMTs. Menveo was non-inferior on these endpoints for serogroup C (Table 4).</p><p>&nbsp;</p><p>Antibody persistence at 5 years after primary vaccination was assessed in the extension study V59P20E1. There was substantial antibody persistence observed against serogroups C, W and Y, with the percentages of subjects with hSBA &ge; 1:8 being 32% and 56% against serogroup C in subjects 2-5 and 6-10 years of age, respectively, 74% and 80% against serogroup W, and 48% and 53% against serogroup Y.&nbsp; GMTs were respectively 6.5 and 12 for serogroup C, 19 and 26 for serogroup W, and 8.13 and 10 for serogroup Y. For serogroup A, 14% and 22% of subjects 2-5 and 6-10 years of age, respectively, had hSBA &ge; 1:8 (GMTs 2.95 and 3.73). Levels for all serogroups were higher than those seen in meningococcal vaccine-na&iuml;ve children of similar ages. The children also received a booster dose of Menveo, 5 years after a single dose primary vaccination. All subjects in both age groups had hSBA &ge; 1:8 across serogroups, with antibody titres several fold higher than seen after the primary vaccination (Table 5).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;5: Persistence of immune responses 5 years after primary vaccination with Menveo, and immune responses 1 month after a booster dose among subjects aged&nbsp;2&nbsp;‑&nbsp;5&nbsp;years and&nbsp;6&nbsp;‑10&nbsp;years at the time of primary vaccination</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:109%"><thead><tr><td><p><strong>Serogroup</strong></p></td><td colspan="4"><p><strong>2‑5&nbsp;years</strong></p></td><td colspan="4"><p><strong>6‑10&nbsp;years</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>5 year persistence</strong></p></td><td colspan="2"><p><strong>1 month after booster</strong></p></td><td colspan="2"><p><strong>5 year persistence</strong></p></td><td colspan="2"><p><strong>1 month after booster</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>%hSBA &ge;1:8</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>hSBA GMTs</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>%hSBA &ge;1:8</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>hSBA GMTs</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>%hSBA &ge;1:8</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>hSBA GMTs</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>%hSBA &ge;1:8</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>hSBA GMTs</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td><p><strong>A</strong></p></td><td><p>N=96</p></td><td><p>N=96</p></td><td><p>N=95</p></td><td><p>N=95</p></td><td><p>N=64</p></td><td><p>N=64</p></td><td><p>N=60</p></td><td><p>N=60</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>14<br /><br />(7, 22)</p></td><td><p>2.95<br /><br />(2.42, 3.61)</p></td><td><p>100<br /><br />(96, 100)</p></td><td><p>361<br /><br />(299, 436)</p></td><td><p>22<br /><br />(13, 34)</p></td><td><p>3.73<br /><br />(2.74, 5.06</p></td><td><p>100<br /><br />(94, 100)</p></td><td><p>350<br /><br />(265, 463)</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p>N=96</p></td><td><p>N=96</p></td><td><p>N=94</p></td><td><p>N=94</p></td><td><p>N=64</p></td><td><p>N=64</p></td><td><p>N=60</p></td><td><p>N=60</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>32<br /><br />(23, 43)</p></td><td><p>6.5<br /><br />(4.75, 8.9)</p></td><td><p>100<br /><br />(96, 100)</p></td><td><p>498<br /><br />(406, 610)</p></td><td><p>56<br /><br />(43, 69)</p></td><td><p>12<br /><br />(7.72, 19)</p></td><td><p>100<br /><br />(94, 100)</p></td><td><p>712<br /><br />(490, 1036)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=96</p></td><td><p>N=96</p></td><td><p>N=95</p></td><td><p>N=95</p></td><td><p>&nbsp;N=64</p></td><td><p>N=64</p></td><td><p>N=60</p></td><td><p>N=60</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>74<br /><br />(64, 82)</p></td><td><p>19<br /><br />(14, 25)</p></td><td><p>100<br /><br />(96, 100)</p></td><td><p>1534<br /><br />(1255, 1873)</p></td><td><p>80<br /><br />(68, 89)</p></td><td><p>26<br /><br />(18, 38)</p></td><td><p>100<br /><br />(94, 100)</p></td><td><p>1556<br /><br />(1083, 2237)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=96</p></td><td><p>N=96</p></td><td><p>N=94</p></td><td><p>N=94</p></td><td><p>&nbsp;N=64</p></td><td><p>N=64</p></td><td><p>N=59</p></td><td><p>N=59</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>48<br /><br />(38, 58)</p></td><td><p>8.13<br /><br />(6.11, 11)</p></td><td><p>100<br /><br />(96, 100)</p></td><td><p>1693<br /><br />(1360, 2107)</p></td><td><p>53<br /><br />(40, 66)</p></td><td><p>10<br /><br />(6.51, 16)</p></td><td><p>100<br /><br />(94, 100)</p></td><td><p>1442<br /><br />(1050, 1979)</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p><u>Immunogenicity in adolescents</u></p><p><u>&nbsp;</u></p><p>In the pivotal study (V59P13), adolescents or adults received either a dose of Menveo (N = 2649) or comparator vaccine (ACWY-D) (N = 875).&nbsp; Sera were obtained both before vaccination and 1 month after vaccination.</p><p>&nbsp;</p><p>In another study (V59P6) conducted in 524 adolescents, the immunogenicity of Menveo was compared to that of ACWY-PS.&nbsp;</p><p>&nbsp;</p><p>In the 11-18 year old population of the pivotal study, V59P13, the immunogenicity of a single dose of Menveo one month post-vaccination is compared with the ACWY-D.&nbsp; Immunogenicity results at one month after Menveo are summarised below in Table 6.</p><p>&nbsp;</p><p>Non-inferiority of Menveo to ACWY-D was demonstrated for all four serogroups using the primary endpoint (hSBA seroresponse). The percentages of subjects with hSBA seroresponse, the percentage of subjects with hSBA &ge; 1:8 and the ratio of GMTs were statistically higher for serogroups A, W-135, and Y in the Menveo group, as compared to the ACWY-D group (Table 6).</p><p>&nbsp;</p><p><strong>Table 6: Serum bactericidal antibody responses following Menveo</strong><strong> one month</strong><strong> after vaccination among subjects aged 11-18 years</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Serogroup</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo/ ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menveo minus </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p><strong>A</strong></p></td><td><p>N=1075</p></td><td><p>N=359</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td><p>75<br />&nbsp;</p><p>(72, 77)</p></td><td><p>66<br />&nbsp;</p><p>(61, 71)</p></td><td><p>&nbsp;</p></td><td><p>8<br />&nbsp;</p><p>(3, 14) *&sect;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>75<br /><br />(73, 78)</p></td><td><p>67<br /><br />(62, 72)</p></td><td><p>-</p></td><td><p>8<br />&nbsp;</p><p>(3, 14) *&sect;</p></td></tr><tr><td><p>GMT</p></td><td><p>29<br />&nbsp;</p><p>(24, 35)</p></td><td><p>18<br />&nbsp;</p><p>(14, 23)</p></td><td><p>1.63<br />&nbsp;</p><p>(1.31, 2.02) *&sect;</p></td><td><p>-</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p>N=1396</p></td><td><p>N=460</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td><p>76<br />&nbsp;</p><p>(73, 78)</p></td><td><p>73<br /><br />(69, 77)</p></td><td><p>&nbsp;</p></td><td><p>2<br />&nbsp;</p><p>(-2, 7)*</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>85<br /><br />(83, 87)</p></td><td><p>85<br /><br />(81, 88)</p></td><td><p>-</p></td><td><p>0<br />&nbsp;</p><p>(-4, 4)*</p></td></tr><tr><td><p>GMT</p></td><td><p>50<br /><br />(39, 65)</p></td><td><p>41<br /><br />(30, 55)</p></td><td><p>1.22<br />&nbsp;</p><p>(0.97, 1.55)*</p></td><td><p>-</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=1024</p></td><td><p>N=288</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td><p>75<br />&nbsp;</p><p>(72, 77)</p></td><td><p>63<br />&nbsp;</p><p>(57, 68)</p></td><td><p>&nbsp;</p></td><td><p>12<br />&nbsp;</p><p>(6, 18) *&sect;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>96<br /><br />(95, 97)</p></td><td><p>88<br /><br />(84, 92)</p></td><td><p>-</p></td><td><p>8<br />&nbsp;</p><p>(4, 12) *&sect;</p></td></tr><tr><td><p>GMT</p></td><td><p>87<br /><br />(74, 102)</p></td><td><p>44<br /><br />(35, 54)</p></td><td><p>2.00<br />&nbsp;</p><p>(1.66, 2.42) *&sect;</p></td><td><p>-</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=1036</p></td><td><p>N=294</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse&Dagger;</p></td><td style="vertical-align:top"><p>68<br />&nbsp;</p><p>(65, 71)</p></td><td style="vertical-align:top"><p>41<br />&nbsp;</p><p>(35, 47)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>27<br />&nbsp;</p><p>(20, 33) *&sect;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>88<br /><br />(85, 90)</p></td><td><p>69<br /><br />(63, 74)</p></td><td><p>-</p></td><td><p>19<br />&nbsp;</p><p>(14, 25) *&sect;</p></td></tr><tr><td><p>GMT</p></td><td><p>51<br /><br />(42, 61)</p></td><td><p>18<br /><br />(14, 23)</p></td><td><p>2.82<br />&nbsp;</p><p>(2.26, 3.52) *&sect;</p></td><td><p>-</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>* Non-inferiority criterion for the primary endpoint met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-D] and &gt; 0.5 for ratio of GMTs [Menveo/ACWY-D]).</p><p>&sect; Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known.</p><p><strong>&nbsp;</strong></p><p>In the subset of subjects aged 11-18 years who were seronegative at baseline (hSBA &lt; 1:4), the proportion of subjects who achieved a hSBA &ge; 1:8 after a dose of Menveo were as follows:&nbsp; serogroup A 75% (780/1039); serogroup C 80% (735/923); serogroup W-135 94% (570/609); serogroup Y 81% (510/630).<em> </em></p><p><strong>&nbsp;</strong></p><p>In the non-inferiority study, V59P6, immunogenicity was assessed among adolescents aged 11-17 years who had been randomised to receive either Menveo or ACWY-PS.&nbsp; For all four serogroups (A, C, W-135 and Y) Menveo was shown to be non-inferior to ACWY-PS vaccine based on seroresponse, proportions achieving hSBA &ge;1:8, and GMTs, and statistically higher based on seroresponse and GMTs.&nbsp; In addition, Menveo was statistically higher to ACWY-PS for serogroups A, C and Y in the percentage of subjects with post-vaccination hSBA &ge; 1:8 (Table 7).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 7: Immunogenicity of one dose of Menveo or ACWY-PS in adolescents, measured at one month post-vaccination</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Endpoint by Serogroup</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo minus ACWY-PS</strong>+</p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo/ACWY-PS</strong>&dagger;</p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>A</strong></p></td><td><p>N=148</p></td><td><p>N=179</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>80<br /><br />(73, 86)</p></td><td><p>41<br /><br />(34, 49)</p></td><td><p>39*<em> </em><sup>&sect;</sup><br /><br />(29, 48)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>81<br /><br />(74, 87)</p></td><td><p>41<br /><br />(34, 49)</p></td><td><p>40*<em> </em><sup>&sect;</sup><br /><br />(30, 49)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>34<br /><br />(26, 44)</p></td><td><p>6.97<br /><br />(5.51, 8.82)</p></td><td><p>-</p></td><td><p>4.87*<em> </em><sup>&sect;</sup><br /><br />(3.41, 6.95)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p><p><strong>C</strong></p></td><td><p>N=148</p></td><td><p>N=177</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>76<br /><br />(68, 82)</p></td><td><p>54<br /><br />(47, 62)</p></td><td><p>21*<em> </em><sup>&sect;</sup><br /><br />(11, 31)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>83<br /><br />(76, 89)</p></td><td><p>63<br /><br />(56, 70)</p></td><td><p>20<br /><br />(10, 29)*<em> </em><sup>&sect;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>58<br /><br />(39, 85)</p></td><td><p>30<br /><br />(22, 43)</p></td><td><p>-</p></td><td><p>1.9*<em> </em><sup>&sect;</sup><br /><br />(1.13, 3.19)</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=146</p></td><td><p>N=173</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p><p><strong>&nbsp;</strong></p></td><td><p>84<br /><br />(77, 90)</p></td><td><p>71<br /><br />(63, 77)</p></td><td><p>14*<em> </em><sup>&sect;</sup><br /><br />(5, 23)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>90<br /><br />(84, 95)</p></td><td><p>86<br /><br />(80, 91)</p></td><td><p>4*<br /><br />(-3, 11)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>49<br /><br />(39, 62)</p></td><td><p>30<br /><br />(24, 37)</p></td><td><p>-</p></td><td><p>1.65*<em> </em><sup>&sect;</sup><br /><br />(1.22, 2.24)</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=147</p></td><td><p>N=177</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p><p>&nbsp;</p></td><td><p>86<br /><br />(79, 91)</p></td><td><p>66<br /><br />(59, 73)</p></td><td><p>20*<em> </em><sup>&sect;</sup><br /><br />(11, 28)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>95<br /><br />(90, 98)</p></td><td><p>81<br /><br />(74, 86)</p></td><td><p>14*<em> </em><sup>&sect;</sup><br /><br />(7, 21)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>100<br /><br />(75, 133)</p></td><td><p>34<br /><br />(27, 44)</p></td><td><p>-</p></td><td><p>2.91*<em> </em><sup>&sect;</sup><br /><br />(1.99, 4.27)</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>+Difference in proportions for Menveo minus ACWY-PS</p><p>&dagger; Ratio of GMTs for Menveo to ACWY-PS.</p><p>* Non inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-PS], &gt;0.5 for ratio of GMTs [Menveo/ACWY-PS])</p><p><sup>&sect;</sup> Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known.</p><p><em><u>Persistence of immune response and booster response in adolescents </u></em></p><p>In study V59P13E1, the persistence of immune responses against serogroups A, C, W-135 and Y was assessed at 21 months, 3 years and 5 years post primary vaccination among subjects aged 11-18 years at the time of vaccination.</p><p>The percentages of subjects with hSBA &ge; 1:8 remained constant against serogroups C, W, and Y from 21 months to 5 years post-vaccination in the Menveo group and decreased slightly over time against serogroup A (Table 8).&nbsp; At 5 years after primary vaccination, there were significantly higher percentages of subjects with hSBA &ge; 1:8 in the Menveo group than in the vaccine-naive control subjects against all the four serogroups.</p><p><strong>Table 8: Persistence of immune responses approximately 21 months, 3 years and 5 years after vaccination with Menveo (subjects were aged 11-18 years at the time of vaccination)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Serogroup</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Timepoint</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Percentages of subjects with hSBA&ge;1:8</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>hSBA GMTs</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>P Value</strong></p><p><strong>Menveo vs ACWY-D</strong></p></td><td style="vertical-align:top"><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>P Value</strong></p><p><strong>Menveo vs ACWY-D</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>A</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=60</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=60</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21 months</p></td><td style="vertical-align:top"><p>45</p><p>(35, 55)</p></td><td style="vertical-align:top"><p>27</p><p>(16, 40)</p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>6.57</p><p>(4.77-9.05)</p></td><td style="vertical-align:top"><p>4.10</p><p>(2.82-5.97)</p></td><td style="vertical-align:top"><p>0.035</p></td></tr><tr><td style="vertical-align:top"><p>3 years</p></td><td style="vertical-align:top"><p>38</p><p>(28, 48)</p></td><td style="vertical-align:top"><p>18</p><p>(10, 30)</p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>5.63</p><p>(3.97-7.99)</p></td><td style="vertical-align:top"><p>3.67</p><p>(2.44-5.53)</p></td><td style="vertical-align:top"><p>0.078</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td style="vertical-align:top"><p>35</p><p>(26, 45)</p></td><td style="vertical-align:top"><p>37</p><p>(25, 50)</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>4.43<br /><br />(3.13-6.26)</p></td><td style="vertical-align:top"><p>4.89</p><p>(3.26-7.33)</p></td><td style="vertical-align:top"><p>0.68</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>C</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=59</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=59</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21 months</p></td><td style="vertical-align:top"><p>61</p><p>(51, 71)</p></td><td style="vertical-align:top"><p>63</p><p>(49, 75)</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>11<br /><br />(8.12-15)</p></td><td style="vertical-align:top"><p>7.64</p><p>(5.4-11)</p></td><td style="vertical-align:top"><p>0.085</p></td></tr><tr><td style="vertical-align:top"><p>3 years</p></td><td style="vertical-align:top"><p>68</p><p>(58, 77)</p></td><td style="vertical-align:top"><p>68</p><p>(54, 79)</p></td><td style="vertical-align:top"><p>0.98</p></td><td style="vertical-align:top"><p>16</p><p>(11-25)</p></td><td style="vertical-align:top"><p>18</p><p>(11-29)</p></td><td style="vertical-align:top"><p>0.81</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td style="vertical-align:top"><p>64</p><p>(54, 73)</p></td><td style="vertical-align:top"><p>63</p><p>(49, 75)</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>14</p><p>(8.83-24)</p></td><td style="vertical-align:top"><p>20</p><p>(11-36)</p></td><td style="vertical-align:top"><p>0.34</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=99</p></td><td style="vertical-align:top"><p>N=57</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=99</p></td><td style="vertical-align:top"><p>N=57</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21 months</p></td><td style="vertical-align:top"><p>86</p><p>(77, 92)</p></td><td style="vertical-align:top"><p>60</p><p>(46, 72)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>18</p><p>(14-25)</p></td><td style="vertical-align:top"><p>9.3</p><p>(6.57-13)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>3 years</p></td><td style="vertical-align:top"><p>85</p><p>(76, 91)</p></td><td style="vertical-align:top"><p>65</p><p>(51, 77)</p></td><td style="vertical-align:top"><p>0.004</p></td><td style="vertical-align:top"><p>31</p><p>(21-46)</p></td><td style="vertical-align:top"><p>17</p><p>(11-28)</p></td><td style="vertical-align:top"><p>0.041</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td style="vertical-align:top"><p>85</p><p>(76, 91)</p></td><td style="vertical-align:top"><p>70</p><p>(57, 82)</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>32</p><p>(21-47)</p></td><td style="vertical-align:top"><p>19</p><p>(12-31)</p></td><td style="vertical-align:top"><p>0.074</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Y</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=60</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=100</p></td><td style="vertical-align:top"><p>N=60</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21 months</p></td><td style="vertical-align:top"><p>71</p><p>(61, 80)</p></td><td style="vertical-align:top"><p>53</p><p>(40, 66)</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>14</p><p>(10-19)</p></td><td style="vertical-align:top"><p>6.77</p><p>(4.73-9.69)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>3 years</p></td><td style="vertical-align:top"><p>69</p><p>(59, 78)</p></td><td style="vertical-align:top"><p>55</p><p>(42, 68)</p></td><td style="vertical-align:top"><p>0.075</p></td><td style="vertical-align:top"><p>14</p><p>(9.68-20)</p></td><td style="vertical-align:top"><p>7.11</p><p>(4.65-11)</p></td><td style="vertical-align:top"><p>0.008</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td style="vertical-align:top"><p>67</p><p>(57, 76)</p></td><td style="vertical-align:top"><p>55</p><p>(42, 68)</p></td><td style="vertical-align:top"><p>0.13</p></td><td style="vertical-align:top"><p>13</p><p>(8.8-20)</p></td><td style="vertical-align:top"><p>8.02</p><p>(4.94-13)</p></td><td style="vertical-align:top"><p>0.078</p></td></tr></tbody></table><p>&nbsp;</p><p>A booster dose of Menveo was administered 3 years after primary vaccination with Menveo or ACWY-D. Both groups showed a robust response to the booster dose of Menveo at one month after vaccination (100% of subjects had hSBA &ge; 1:8 across serogroups) and this response largely persisted through 2 years after the booster dose for serogroups C, W and Y (with 87% to 100% of subjects with hSBA &ge; 1:8 across serogroups). A small decline was observed in percentages of subjects with hSBA &ge; 1:8 against serogroup A, although percentages were still high (77% to 79%).</p><p>GMTs declined over time as expected but remained between 2- and 8-fold higher than pre-booster values (Table 8).</p><p>&nbsp;</p><p>In study V59P6E1, at one year post-vaccination, the percentage of Menveo recipients with hSBA &ge; 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C, W-135 and Y, and similar between the two study groups for serogroup A. hSBA GMTs for serogroups W-135 and Y were higher among Menveo recipients. In 5 years post-vaccination, the percentage of Menveo recipients with hSBA &ge; 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C and Y. Higher hSBA GMTs were observed for serogroups W-135 and Y (Table 9).</p><p>&nbsp;</p><p><strong>Table 9: Persistence of immune responses approximately 12 months and 5 years after vaccination with Menveo and ACWY-PS (subjects were aged 11-18 years at the time of vaccination)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:102%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Serogroup</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Timepoint</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Percentages of subjects with hSBA&ge;1:8</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>hSBA GMTs</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-PS</strong></p></td><td style="vertical-align:top"><p><strong>P Value</strong></p><p><strong>Menveo vs ACWY-PS</strong></p></td><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-PS</strong></p></td><td style="vertical-align:top"><p><strong>P Value</strong></p><p><strong>Menveo vs ACWY- PS</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>A</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12 months</p></td><td><p>41%<br />&nbsp;</p><p>(27, 56)<br />&nbsp;</p></td><td><p>43%<br /><br />(28, 59)<br />&nbsp;</p></td><td><p>0.73</p></td><td><p>&nbsp;5.19<br /><br />(3.34, 8.09)</p></td><td><p>6.19<br /><br />(3.96, 9.66)</p></td><td><p>0.54</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td><p>30%<br /><br />(18, 45)</p></td><td><p>44%<br /><br />(30, 59)</p></td><td><p>0.15</p></td><td><p>5.38<br /><br />(3.29, 8.78)</p></td><td><p>7.75<br /><br />(4.83, 12)</p></td><td><p>0.24</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>C</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12 months</p></td><td><p>82%<br /><br />(68, 91)</p></td><td><p>52%<br /><br />(37, 68)</p></td><td><p>&lt;0.001</p></td><td><p>29<br /><br />(15, 57)</p></td><td><p>17<br /><br />(8.55, 33)</p></td><td><p>0.22</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td><p>76%<br /><br />(62, 87)</p></td><td><p>62%<br /><br />(47, 75)</p></td><td><p>0.042</p></td><td><p>21<br /><br />(12, 37)</p></td><td><p>20<br /><br />(12, 35)</p></td><td><p>0.92</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12 months</p></td><td><p>92%<br /><br />(80, 98)</p></td><td><p>52%<br /><br />(37, 68)</p></td><td><p>&lt;0.001</p></td><td><p>41<br /><br />(26, 64)</p></td><td><p>10<br /><br />(6.41, 16)</p></td><td><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td><p>72%<br /><br />(58, 84)</p></td><td><p>56%<br /><br />(41, 70)</p></td><td><p>0.093</p></td><td><p>30<br /><br />(18, 52)</p></td><td><p>13<br /><br />(7.65, 22)</p></td><td><p>0.012</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Y</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td><td><p>N=50</p></td><td><p>N=50</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12 months</p></td><td><p>78%<br /><br />(63, 88)</p></td><td><p>50%<br /><br />(35, 65)</p></td><td><p>0.001</p></td><td><p>34<br /><br />(20, 57)</p></td><td><p>9.28<br /><br />(5.5, 16)</p></td><td><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>5 years</p></td><td><p>76%<br /><br />(62, 87)</p></td><td><p>50%<br /><br />(36, 64)</p></td><td><p>0.002</p></td><td><p>30<br /><br />(18, 49)</p></td><td><p>8.25<br /><br />(5.03, 14)</p></td><td><p>&lt;0.001</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>A booster dose of Menveo was administered 5 years after primary vaccination with Menveo or ACWY-PS. At 7 days after the booster dose, 98%-100% of subjects who previously received Menveo and 73%-84% of subjects who previously received ACWY-PS achieved hSBA &ge;1:8 against serogroups A, C, W-135 and Y. At one month post-vaccination, the percentages of subjects with hSBA&ge;1:8 were 98%-100% and 84%-96%, respectively.</p><p>A significant increase in the hSBA GMTs against all four serogroups was also observed at 7 and 28 days after the booster dose (Table 10).<em> </em></p><p><strong>Table 10: Response to Booster: bactericidal antibody responses to Menveo booster administered at 3 or 5 years after the primary vaccination with Menveo or ACWY-D or ACWY-PS in subjects aged 11-17 years </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:563px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Serogroup</strong></p></td><td rowspan="3" style="vertical-align:top"><p><strong>Time point</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Percentages of subjects with hSBA&ge;1:8</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>hSBA GMTs</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>V59P13E1</strong></p><p><strong>(3 years post-vaccination)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>V59P6E1</strong></p><p><strong>(5 years post-vaccination)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>V59P13E1</strong></p><p><strong>(3 years post-vaccination)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>V59P6E1</strong></p><p><strong>(5 years post-vaccination)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-D</strong></p></td><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-PS</strong></p></td><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-D</strong></p></td><td style="vertical-align:top"><p><strong>Menveo</strong></p></td><td style="vertical-align:top"><p><strong>ACWY-PS</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>A</strong></p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pre-booster</p></td><td style="vertical-align:top"><p>21%</p><p>(10, 37)</p></td><td style="vertical-align:top"><p>20%</p><p>(8, 39)</p></td><td style="vertical-align:top"><p>29%<br /><br />(17, 43)</p></td><td style="vertical-align:top"><p>43%<br /><br />(29, 58)</p></td><td style="vertical-align:top"><p>2.69<br /><br />(1.68, 4.31)</p></td><td style="vertical-align:top"><p>2.81<br /><br />(1.68, 4.69)</p></td><td style="vertical-align:top"><p>5.16<br /><br />(3.46, 7.7)</p></td><td style="vertical-align:top"><p>7.31<br /><br />(4.94, 11)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>73%<br /><br />(59, 85)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1059<br /><br />(585, 1917)</p></td><td style="vertical-align:top"><p>45<br /><br />(25, 80)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>100%<br /><br />(92, 100)</p></td><td style="vertical-align:top"><p>100%<br /><br />(88, 100)</p></td><td style="vertical-align:top"><p>98%<br /><br />(89, 100)</p></td><td style="vertical-align:top"><p>94%<br /><br />(83, 99)</p></td><td style="vertical-align:top"><p>326<br /><br />(215, 494)</p></td><td style="vertical-align:top"><p>390<br /><br />(248, 614)</p></td><td style="vertical-align:top"><p>819<br /><br />(514, 1305)</p></td><td style="vertical-align:top"><p>147<br /><br />(94, 232)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>79%</p><p>(63, 90)</p></td><td style="vertical-align:top"><p>77%</p><p>(58, 90)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>22</p><p>(12, 41)</p></td><td style="vertical-align:top"><p>20</p><p>(10, 39)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>C</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pre-booster</p></td><td style="vertical-align:top"><p>55%<br /><br />(39, 70)</p></td><td style="vertical-align:top"><p>60%<br /><br />(41, 77)</p></td><td style="vertical-align:top"><p>78%<br /><br />(63, 88)</p></td><td style="vertical-align:top"><p>61%<br /><br />(46, 75)</p></td><td style="vertical-align:top"><p>16<br /><br />(8.66, 31)</p></td><td style="vertical-align:top"><p>15<br /><br />(7.46, 30)</p></td><td style="vertical-align:top"><p>20<br /><br />(13, 33)</p></td><td style="vertical-align:top"><p>19<br /><br />(12, 31)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>78%<br /><br />(63, 88)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1603<br /><br />(893, 2877)</p></td><td style="vertical-align:top"><p>36<br /><br />(20, 64)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>100%</p><p>(92, 100)</p></td><td style="vertical-align:top"><p>100%</p><p>(88, 100)</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>84%<br /><br />(70, 93)</p></td><td style="vertical-align:top"><p>597<br /><br />(352, 1014)</p></td><td style="vertical-align:top"><p>477<br /><br />(268, 849)</p></td><td style="vertical-align:top"><p>1217<br /><br />(717, 2066)</p></td><td style="vertical-align:top"><p>51<br /><br />(30, 86)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>95%</p><p>(84-99)</p></td><td style="vertical-align:top"><p>87%</p><p>(69-96)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>124</p><p>(62-250)</p></td><td style="vertical-align:top"><p>61</p><p>(29-132)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>W-135</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=41</p></td><td style="vertical-align:top"><p>N=29</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=41</p></td><td style="vertical-align:top"><p>N=29</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pre-booster</p></td><td style="vertical-align:top"><p>88%<br /><br />(74, 96)</p></td><td style="vertical-align:top"><p>83%<br /><br />(64, 94)</p></td><td style="vertical-align:top"><p>73%<br /><br />(59, 85)</p></td><td style="vertical-align:top"><p>55%<br /><br />(40, 69)</p></td><td style="vertical-align:top"><p>37<br /><br />(21, 65)</p></td><td style="vertical-align:top"><p>21<br /><br />(11, 38)</p></td><td style="vertical-align:top"><p>29<br /><br />(17, 49)</p></td><td style="vertical-align:top"><p>12<br /><br />(7.02, 19)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>84%<br /><br />(70, 93)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>1685<br /><br />(1042, 2725)</p></td><td style="vertical-align:top"><p>34<br /><br />(21, 54)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>100%</p><p>(91, 100)</p></td><td style="vertical-align:top"><p>100%</p><p>(88, 100)</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>92%<br /><br />(80, 98)</p></td><td style="vertical-align:top"><p>673</p><p>(398, 1137)</p></td><td style="vertical-align:top"><p>1111</p><p>(631, 1956)</p></td><td style="vertical-align:top"><p>1644<br /><br />(1090, 2481)</p></td><td style="vertical-align:top"><p>47<br /><br />(32, 71)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>100%</p><p>(91, 100)</p></td><td style="vertical-align:top"><p>97%</p><p>(82, 100)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>93</p><p>(58, 148)</p></td><td style="vertical-align:top"><p>110</p><p>(67, 183)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Y</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=42</p></td><td style="vertical-align:top"><p>N=30</p></td><td style="vertical-align:top"><p>N=49</p></td><td style="vertical-align:top"><p>N=49</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pre-booster</p></td><td style="vertical-align:top"><p>74%<br /><br />(58, 86)</p></td><td style="vertical-align:top"><p>53%<br /><br />(34, 72)</p></td><td style="vertical-align:top"><p>78%<br /><br />(63, 88)</p></td><td style="vertical-align:top"><p>51%<br /><br />(36, 66)</p></td><td style="vertical-align:top"><p>14<br /><br />(8.15, 26)</p></td><td style="vertical-align:top"><p>8.9<br /><br />(4.76, 17)</p></td><td style="vertical-align:top"><p>28<br /><br />(18, 45)</p></td><td style="vertical-align:top"><p>7.8<br /><br />(4.91, 12)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7 days</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>98%<br /><br />(89, 100)</p></td><td style="vertical-align:top"><p>76%<br /><br />(61, 87)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>2561<br /><br />(1526, 4298)</p></td><td style="vertical-align:top"><p>21<br /><br />(13, 35)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>100%</p><p>(92, 100)</p></td><td style="vertical-align:top"><p>100%</p><p>(88, 100)</p></td><td style="vertical-align:top"><p>100%<br /><br />(93, 100)</p></td><td style="vertical-align:top"><p>96%<br /><br />(86, 100)</p></td><td style="vertical-align:top"><p>532</p><p>(300, 942)</p></td><td style="vertical-align:top"><p>454</p><p>(243, 846)</p></td><td style="vertical-align:top"><p>2092<br /><br />(1340, 3268)</p></td><td style="vertical-align:top"><p>63<br /><br />(41, 98)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>95%</p><p>(84, 99)</p></td><td style="vertical-align:top"><p>93%</p><p>(78, 99)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>55</p><p>(30, 101)</p></td><td style="vertical-align:top"><p>46</p><p>(24, 89)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Immunogenicity in adults (19-55 years)</u></p><p><u>&nbsp;</u></p><p>In the pivotal immunogenicity trial, V59P13, immune responses to Menveo were assessed among adults aged 19 to 55 years. Results are presented in Table 11.<strong> </strong>Non-inferiority of Menveo to ACWY-D was demonstrated for all four serogroups using the primary endpoint (hSBA seroresponse) (Table 11).&nbsp; Both hSBA GMTs and the percentage of subjects with hSBA seroresponse were statistically higher for serogroups C, W-135, and Y among Menveo recipients than in ACWY-D recipients.&nbsp; The percentage of subjects with hSBA &ge; 1:8 was statistically higher for serogroups C and Y among Menveo recipients, as compared to the corresponding groups in ACWY-D recipients (Table 11).</p><p><strong>&nbsp;</strong></p><p><strong>Table 11: </strong><strong>Serum bactericidal antibody responses following Menveo</strong><strong> one month</strong><strong> after vaccination among subjects aged 19-55 years</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Endpoint by Serogroup</strong></p></td><td><p><strong>Menveo </strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong><em>&nbsp;</em></strong><strong>ACWY-D</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo /ACWY-D</strong><strong> </strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo minus ACWY-D (95% CI)</strong></p></td></tr><tr><td><p><strong>A</strong></p></td><td><p>N=963</p></td><td><p>N=321</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>67<br />&nbsp;</p><p>(64, 70)</p></td><td><p>68<br />&nbsp;</p><p>(63, 73)</p></td><td><p>&nbsp;</p></td><td><p>-1</p><p>(-7, 5)*</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>69<br /><br />(66, 72)</p></td><td><p>71<br /><br />(65, 76)</p></td><td><p>-</p></td><td><p>-2<br />&nbsp;</p><p>(-7, 4)*</p></td></tr><tr><td><p>GMT</p></td><td><p>31<br /><br />(27, 36)</p></td><td><p>30<br /><br />(24, 37)</p></td><td><p>1.06<br />&nbsp;</p><p>(0.82, 1.37)*</p></td><td><p>-</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p>N=902</p></td><td><p>N=300</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>68<br />&nbsp;</p><p>(64, 71)</p></td><td><p>60<br />&nbsp;</p><p>(54, 65)</p></td><td><p>&nbsp;</p></td><td><p>8<br />&nbsp;</p><p>(2, 14)*<sup> &sect;</sup>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>80<br /><br />(77, 83)</p></td><td><p>74<br /><br />(69, 79)</p></td><td><p>-</p></td><td><p>6<br />&nbsp;</p><p>(1, 12)<em>*</em><sup> &sect;</sup>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>50<br /><br />(43, 59)</p></td><td><p>34<br /><br />(26, 43)</p></td><td><p>1.50<br />&nbsp;</p><p>(1.14, 1.97)<em>*</em><sup> &sect;</sup>&nbsp;</p></td><td><p>-</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=484</p></td><td><p>N=292</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>50<br />&nbsp;</p><p>(46, 55)</p></td><td><p>41<br />&nbsp;</p><p>(35, 47)</p></td><td><p>&nbsp;</p></td><td><p>9<br />&nbsp;</p><p>(2, 17) *<sup> &sect;</sup>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>94<br /><br />(91, 96)</p></td><td><p>90<br /><br />(86, 93)</p></td><td><p>-</p></td><td><p>4<br />&nbsp;</p><p>(0, 9)*</p></td></tr><tr><td><p>GMT</p></td><td><p>111<br /><br />(93, 132)</p></td><td><p>69<br /><br />(55, 85)</p></td><td><p>1.61<br />&nbsp;</p><p>(1.24, 2.1)<em>*</em><sup> &sect;</sup>&nbsp;</p></td><td><p>-</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=503</p></td><td><p>N=306</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>56<br />&nbsp;</p><p>(51, 60)</p></td><td style="vertical-align:top"><p>40<br />&nbsp;</p><p>(34, 46)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>16<br />&nbsp;</p><p>(9, 23) *<sup> &sect;</sup>&nbsp;</p></td></tr><tr><td><p>% &ge; 1:8</p></td><td><p>79<br /><br />(76, 83)</p></td><td><p>70<br /><br />(65, 75)</p></td><td><p>-</p></td><td><p>9<br />&nbsp;</p><p>(3, 15)<em>*</em><sup> &sect;</sup>&nbsp;</p></td></tr><tr><td><p>GMT</p></td><td><p>44<br /><br />(37, 52)</p></td><td><p>21<br /><br />(17, 26)</p></td><td><p>2.10<br />&nbsp;</p><p>(1.60, 2.75)<em>*</em><sup> &sect;</sup>&nbsp;</p></td><td><p>-</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>* Non-inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-D] and &gt; 0.5 for ratio of GMTs [Menveo/ACWY-D]).</p><p><sup>&sect;</sup> Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known.</p><p>In the subset of subjects aged 19-55 years who were seronegative at baseline, the proportion of subjects who achieved a hSBA &ge; 1:8 after a dose of Menveo were as follows: serogroup A 67% (582/875); serogroup C 71% (401/563); serogroup W-135 82% (131/160); serogroup Y 66% (173/263).</p><p>&nbsp;</p><p>The onset of immune response after the primary vaccination with Menveo in healthy subjects 18 through 22 years of age was evaluated in study V59P6E1. At 7 days post-vaccination, 64% of subjects achieved hSBA &ge;1:8 against serogroup A and 88% through 90% of subjects had bactericidal antibodies against serogroups C, W-135 and Y.&nbsp; At one month post-vaccination, 92% through 98% of subjects had hSBA &ge;1:8 against serogroups A, C, W-135 and Y. A robust immune response as measured by hSBA GMTs against all serogroups was also observed at 7 days (GMTs 34 through 70) and 28 days (GMTs 79 through 127) after a single dose vaccination.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity in older adults (56-65 years)</u></p><p><u>&nbsp;</u></p><p>The comparative immunogenicity of Menveo vs. ACWY-PS was evaluated in subjects aged 56-65 years, in study V59P17.&nbsp; The proportion of subjects with hSBA &ge; 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically higher for serogroups A and Y for all endpoints (seroresponse, hSBA &ge; 1:8, and GMT). In addition, statistically higher responses among Menveo recipients were observed for serogroup C GMTs (Table 12).&nbsp;</p><p>&nbsp;</p><p><strong>Table 12: Immunogenicity of one dose of Menveo or ACWY-PS in adults aged 56-65 years, measured at one month post-vaccination.</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td><p><strong>Endpoint by Serogroup</strong></p></td><td><p><strong>Menveo</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo/ ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Menveo minus&nbsp; ACWY-PS</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td><p><strong>A</strong></p></td><td><p>N=83</p></td><td><p>N=41</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>86%<br />&nbsp;</p><p>(76, 92)</p></td><td><p>61%<br />&nbsp;</p><p>(45,76)</p></td><td><p>-</p></td><td><p>25<br />&nbsp;</p><p>(9, 41)*<sup> &sect;</sup></p></td></tr><tr><td><p>% hSBA &ge; 1:8</p><p>&nbsp;</p></td><td><p>87<br />&nbsp;</p><p>(78, 93)</p></td><td><p>63<br />&nbsp;</p><p>(47, 78)</p></td><td><p>-</p></td><td><p>23<br /><br />(8, 40)*<sup> &sect;</sup></p></td></tr><tr><td><p>GMT</p></td><td><p>111</p><p>(70,175)</p></td><td><p>21</p><p>(11,39)</p></td><td><p>5.4</p><p>(2.47, 12)*<sup> &sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>C</strong></p></td><td><p>N=84</p></td><td><p>N=41</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>83%<br />&nbsp;</p><p>(74, 91)</p></td><td><p>73%<br />&nbsp;</p><p>(57, 86)</p></td><td><p>-</p></td><td><p>10<br />&nbsp;</p><p>(-4, 27)*</p></td></tr><tr><td><p>% hSBA &ge; 1:8</p><p>&nbsp;</p></td><td><p>90<br />&nbsp;</p><p>(82, 96)</p></td><td><p>83<br />&nbsp;</p><p>(68, 93)</p></td><td><p>-</p></td><td><p>8<br /><br />(-4, 23)*</p></td></tr><tr><td><p>GMT</p></td><td><p>196</p><p>(125,306)</p></td><td><p>86</p><p>(45,163)</p></td><td><p>2.27</p><p>(1.05, 4.95)*<sup> &sect;</sup></p></td><td><p>-</p></td></tr><tr><td><p><strong>W-135</strong></p></td><td><p>N=82</p></td><td><p>N=39</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>61%<br />&nbsp;</p><p>(50, 72)</p></td><td><p>54%<br />&nbsp;</p><p>(37,70)</p></td><td><p>-</p></td><td><p>7<br />&nbsp;</p><p>(-11, 26)<sup> </sup></p></td></tr><tr><td><p>% hSBA &ge; 1:8</p><p>&nbsp;</p></td><td><p>94<br />&nbsp;</p><p>(86, 98)</p></td><td><p>95<br />&nbsp;</p><p>(83, 99)</p></td><td><p>-</p></td><td><p>-1<br /><br />(-9, 11 )*</p></td></tr><tr><td><p>GMT</p></td><td><p>164<br /><br />(112,240)</p></td><td><p>132<br /><br />(76,229)</p></td><td><p>1.24<br /><br />(0.64, 2.42)*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Y</strong></p></td><td><p>N=84</p></td><td><p>N=41</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>% Seroresponse<sup>&Dagger;</sup></p></td><td><p>77%<br />&nbsp;</p><p>(67, 86)</p></td><td><p>54%<br />&nbsp;</p><p>(37,69)</p></td><td><p>-</p></td><td><p>24<br />&nbsp;</p><p>(6, 41)*<sup> &sect;</sup></p></td></tr><tr><td><p>% hSBA &ge; 1:8</p><p>&nbsp;</p></td><td><p>88<br />&nbsp;</p><p>(79, 94)</p></td><td><p>68<br />&nbsp;</p><p>(52, 82)</p></td><td><p>-</p></td><td><p>20<br /><br />(5, 36)*<sup> &sect;</sup></p></td></tr><tr><td><p>GMT</p></td><td><p>121<br /><br />(76,193)</p></td><td><p>28<br /><br />(15,55)</p></td><td><p>4.25<br /><br />(1.89, 9.56)*<sup> &sect;</sup></p></td><td><p>-</p></td></tr></tbody></table><p>&Dagger; Seroresponse was defined as: a) post-vaccination hSBA &ge;1:8 for subjects with a pre-vaccination hSBA &lt;1:4; or, b) at least 4-fold higher than baseline titres for subjects with a pre-vaccination hSBA &ge;1:4.</p><p>* Non-inferiority criterion met (the lower limit of the two-sided 95% CI &gt;-10 % for vaccine group differences [Menveo minus ACWY-PS] and &gt; 0.5 for ratio of GMTs [Menveo/ACWY-PS]).</p><p><sup>&sect;</sup> Immune response was statistically higher (the lower limit of the two-sided 95% CI &gt;0% for vaccine group differences or &gt; 1.0 for ratio of GMTs); however the clinical relevance of higher post-vaccination immune responses is not known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evaluation of pharmacokinetic properties is not required for vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on animal studies that are appropriate for the safety assessment of vaccines.</p><p><strong>Animal toxicology and/or pharmacology</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_ea79310e-8c6b-40aa-a9ee-41fe22ec5b0c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Menveo was immunogenic in mice and rabbits. In three repeat-dose toxicity studies in rabbits there was no evidence of systemic toxicity and the vaccine was locally well tolerated.</p><p><strong>Reproductive Toxicology</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_1bf45f14-6b5b-421d-959f-0b76d825ee50 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>In a reproductive and developmental toxicity study, female rabbits received three intramuscular doses of Menveo before mating and two additional doses during gestation. Each dose administered to rabbits was equivalent to the human dose and, based on body weights, approximately 10 times the human dose. There were no teratogenic effects, and no findings of increased foetal loss, mortality or resorptions, reductions in body weight of foetuses, or other developmental abnormalities in the offspring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u>:<u> </u></p><p>Potassium dihydrogen phosphate (5 mm)</p><p>Sucrose (12.5 mg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><u>Solution</u>:</p><p>Sodium chloride (4.5 mg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Sodium dihydrogen phosphate monohydrate<strong><em> </em></strong>(2.5 mm)</p><p>Disodium phosphate dihydrate (7.5 mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Water for injections (q.b 0.5 ml)</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.<strong><em> </em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.</p><p>Keep the container in the outer carton in order to protect from light. After reconstitution, the product should be used immediately. However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial-Syringe presentation</u></p><ul><li>Powder for 1 dose in a vial (type I glass) with a stopper (obutyl rubber)</li><li>Solution for 1 dose in a pre-filled syringe (type I glass) with a tip cap (type I elastomeric closure with natural rubber latex or type II elastomeric closure that has no detectable natural rubber latex).</li></ul><p><strong><em>&nbsp;</em></strong></p><p>Pack size of one dose: 1 vial of powder plus 1 pre-filled syringe.</p><p><em>&nbsp;</em></p><p><u>Vial-Vial presentation</u></p><ul><li>Powder for 1 dose in a vial (type I glass) with a stopper (obutyl rubber)</li><li>Solution for 1 dose in a vial (type I glass) with a stopper (butyl rubber).</li></ul><p><strong><em>&nbsp;</em></strong></p><p>Pack size of one dose: 1 vial of powder plus 1 vial of solution or pack size of 5 doses: 5 vials of powder plus 5 vials of solution.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The contents of the two components in the two different containers (MenA powder and MenCWY solution) are to be mixed prior to vaccination providing 1 dose of 0.5 ml.</strong></p><p><u>For vial-syringe presentation:</u></p><p>Menveo must be prepared for administration by reconstituting the powder (in vial) with the solution (in pre-filled syringe).</p><p>The components of the vaccine should be visually inspected before and after reconstitution.</p><p>&nbsp;</p><p>Remove the tip cap from the syringe and attach a suitable needle for the withdrawal (21G, 1 &frac12; inch length or a 21G, 40 mm length). Use the whole contents of the syringe to reconstitute the powder.&nbsp;</p><p>&nbsp;</p><p>Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.</p><p>&nbsp;</p><p>Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.</p><p>&nbsp;</p><p>Prior to injection, change the needle for one suitable for the administration. After reconstitution, the product should be used immediately. However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25&deg;C.<strong><em><s> </s></em></strong></p><p><u>&nbsp;</u></p><p><u>For vial-vial presentation:</u></p><p>Menveo must be prepared for administration by reconstituting the powder (in vial) with the solution (in vial).</p><p>The components of the vaccine should be visually inspected before and after reconstitution.</p><p>&nbsp;</p><p>Using a syringe and a suitable needle (21G, 1 &frac12; inch length or a 21G, 40 mm length) withdraw the entire content of the vial of solution and inject into the vial of powder to reconstitute the MenA conjugate component.</p><p>&nbsp;</p><p>Invert and shake the vial vigorously and then withdraw 0.5 ml of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.</p><p>&nbsp;</p><p>Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.</p><p>&nbsp;</p><p>Prior to injection, change the needle for one suitable for the administration. Ensure that no air bubbles are present in the syringe before injecting the vaccine.</p><p>&nbsp;</p><p>After reconstitution, the product should be used immediately. However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25&deg;C.</p><p><strong>&nbsp;</strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>menveo is trademark owned by or licensed to GSK group of companies.<!--[if supportFields]><b><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"MS Mincho";text-transform:uppercase;layout-grid-mode:line'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&copy;2023 GSK,all rights reserved</p><p><strong>Manufactured by:</strong></p><p>- GSK vaccines Srl Bellaria Rosia, Italy</p><p>Tel: (39) 0 577 243111</p><p>Fax: (39) 0 577 243074</p><p>Or alternatively by:</p><p>Patheon Italia S.p.A. -</p><p>Monza (MB) ,ITALY &ndash;20900 iale G.B. Stucchi, 110 ,V</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glaxo Saudi Arabia Ltd.* Jeddah, KSA 
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia 
*Member of the GlaxoSmithKline group of companies


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DATE OF REVISION OF THE TEXT
GDS version number: GDS 13
Version date: 1 Feb 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>